NON-THEMATIC REVIEW

The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network

Lakshmanane Boominathan

Abstract The tumor suppressor p53 homologues, TA-p73, and p63 have been shown to function as tumor suppressors. However, how they function as tumor suppressors remains elusive. Here, I propose a number of tumor suppressor pathways that illustrate how the TA-p73 and p63 could function as negative regulators of invasion, metastasis, and cancer stem cells (CSCs) proliferation. Furthermore, I provide molecular insights into how TA-p73 and p63 could function as tumor suppressors. Remarkably, the guardians—p53, p73, and p63—of the genome are in control of most of the known tumor suppressor miRNAs, tumor suppressor genes, and metastasis suppressors by suppressing c-myc through miR-145/let-7/miR-34/TRIM32/PTEN/FBXW7. In particular, p53 and TA-p73/p63 appear to upregulate the expression of (1) tumor suppressor miRNAs, such as let-7, miR-34, miR-15/16a, miR-145, miR-29, miR-26, miR-30, and miR-146a; (2) tumor suppressor genes, such as PTEN, RBs, CDKN1a/b/c, and CDKN2a/b/c/d; (3) metastasis suppressors, such as Raf kinase inhibitory protein, CycG2, and DEC2, and thereby they enlarge their tumor suppressor network to inhibit tumorigenesis, invasion, angiogenesis, migration, metastasis, and CSCs proliferation.

Keywords p53/p73/p63 · c-myc · PTEN · miRNAs · Metastasis · CSCs

1 Introduction

MiRNAs (miRNAs/miRs) are small non-coding RNAs. They bind to 3′UTR of mRNAs in a sequence specific manner. They either repress translation or promote degradation of mRNAs. p53 functions as a transcription factor and it controls the expression of a number of genes to promote tumor suppression and genome integrity. It is the most frequently mutated gene in human cancer.

miRNAs have been shown to function downstream of the tumor suppressor p53. MiRNAs, such as miR-34, miR-192/215, miR-107, and miR-145, are known transcriptional targets of p53. They could also be transactivated by p53 homologues, such as p73 and p63, as they are known to transactivate p53's transcriptional targets. In addition, a number of tumor suppressor miRNAs that have recently been discovered appear to play a key role in controlling tumorigenesis. However, whether they are regulated by the tumor suppressor p53/p73/p63 is not known.

Unlike p53, p73 gene is not frequently mutated in human cancer. However, TA-p73 promoter is hypermethylated in a number of human cancers [1]. A number of studies suggest that it responds to DNA damage and maintains genome integrity, suggesting that it could function as a tumor suppressor. However, how it functions as a tumor suppressor remains elusive. I have proposed previously a tumor suppressor pathway—*E2F-1/2-TA-p73/p63-p57kip2/14-3-3σ/JunB-BRCA/INK4/ARF*—to explain how it functions as a tumor suppressor [1]. Remarkably, six components of–E2F1 [2], p73 [3], p63 [4, 5], p57kip2 [6], 14-3-3σ [7, 8], and INK4a/b [9]—the proposed tumor suppressor pathway appear to be either poorly expressed or hypermethylated (silenced) in transitional cell carcinoma of the bladder, suggesting the conserved nature of this tumor suppressor pathway. Furthermore, (a) tuberous sclerosis 1 (TSC1), a putative/proven transcriptional target of p73/FoxO3a, has been shown to be mutated (14. 5%) in bladder cancer [10]; (b) LZTS-1/FEZ1 (fasciculation and elongation protein zeta 1), a putative transcriptional target of p73/p63, protein expression is decreased in 37% of primary

L. Boominathan (✉)
Genome Discovery,
49, Nattar Main Street,
Puducherry 605 004, India
e-mail: lakshmanan.boominathan@gmail.com

transitional bladder carcinoma[11]; (c) PTEN, a transcriptional target of p53 (possibly, p73/p63), expression has shown to be decreased or absent in primary bladder cancer patients (53%) and in advanced bladder cancer patients (94%) [12]. (d) Acute myeloid leukemia (AML)-2/Runx-3, a putative target of p63, has shown to be hypermethylated (73%) in primary bladder cancer [13]. (e) miR-145/143/200/101/29/34, a proven/putative transcriptional target of p53/p73/p63, expression is reduced or silenced in bladder cancer [14, 15]. (f) miR-let-7, a putative/proven transcriptional target of E2F-1/p53/p73/p63, appears to target proto-oncogenes—PI3-K and Ha-ras—that play a key role in bladder cancer [16–18]. Based on these data, here I propose a tumor suppressor pathway—*E2F-1/2-TA-p73/p63-p57kip2/LZTS1/TSC1/PTEN1/RBs/14-3-3σ/AML2/INK4-miR 145/143/let-7/101/29/34*—that could play a critical role in the inhibition of transitional bladder carcinoma. Additionally, this pathway could play a role in the inhibition of lung adenocarcinoma development, as some of these genes also appear to be mutated in lung cancers.

Further, in support of the notion that p73 functions as a tumor suppressor, it has recently been shown that TA-p73 knockout mice are prone to lung adenocarcinoma, suggesting that it could indeed function as a tumor suppressor gene [19]. E2F-1/2 is a transcriptional activator of TA-p73. Remarkably, *E2F1−/−/E2F1−/−E2F2+/−/E2F1−/+E2F2−/−* mice are also prone to highly invasive adenocarcinomas of the lung (non-small cell lung carcinomas) [1]. Together, these data suggest that E2F1/2 could mediate its tumor suppressor function through its transcriptional target TA-p73 [1, 19]. Further, it has been shown that increased expression of the tumor suppressor ARF co-localizes with the tumor suppressor BRCA1 and thereby increases its expression [1, 20]. This data suggests that both ARF and BRCA1 could play a role in p73-dependent tumor suppression [20]. Interestingly, E2F1−/−, p73+/−, TAp73−/−, and BRCA2−/− mice have been shown to develop lymphomas [1, 19, 21–23], suggesting that they could co-operate with each other in the inhibition of lymphoma development.

Unlike TA-p73, TA-p63 promoter is not frequently hypermethylated. However, TA-p63 expression is downregulated in bladder cancer [4, 5]. I have proposed for the first time that p63 could increase the expression of the tumor suppressor AML-1/Runx1, which in turn could increase the expression of the tumor suppressor p14ARF/INK4a (Boominathan, invention disclosure, 2003). Increased expression of p14ARF/INK4a has been shown to promote senescence—a tumor suppressor mechanism—in a number of cell types, indicating that the *p63-AML-1-p14ARF/INK4a* pathway could promote tumor suppression in a cell context-dependent manner (Boominathan, invention disclosure, 2003). In addition, p63/p73, by transactivating the chronic myeloid leukemia (CML)/B-cell tumor suppressor JunB, it

could increase the expression of the tumor suppressor INK4a, as JunB has been shown to increase the expression of INK4a [1, 24–27; invention disclosure, 2002, Boominathan]. Evidently, p73 has shown to be hypermethylated in an AML, acute T-cell lymphoblastic leukemia, and Burkitt lymphoma [1, 28], whereas p63 expression appears to be mutated (11.8%) in CML [29]. Therefore, I have proposed for the first time that p63/p73, by increasing the AML-1/JunB-ARF/Ink4a pathway, it could function as a tumor suppressor in myeloid leukemia (invention disclosure, 2002/2003, Boominathan). To determine whether p63/p73 synergizes with JunB/AML-1 in tumor suppression, one can cross *p63+/−; p73+/−* mice with *JunB+/−; AML-1/2+/−* mice.

Further, KAI1/CD82, a cell surface glycoprotein, has been shown to inhibit EGFR signaling, tumorigenesis, and metastasis. It also appears to promote senescence. p53 has been shown to synergize with both AP-2 and JunB in the induction of KAI1/CD82 expression [30]. Interestingly, both p73 and p63 have been shown to increase the expression of JunB and AP-2, suggesting that they could also induce the expression of KAI1/CD82 [1, 31, 32]. Furthermore, AP-2α, a transcriptional target of p53, has been shown to induce the metastasis suppressor KiSS [33], suggesting that p53 may increase the expression of KiSS through AP-2α. Interestingly, KiSS expression has shown to be lost in metastatic/invasive bladder cancers [34], suggesting that the *p53/p73/p63-JunB/AP-2/KAI1-KiSS* pathway could inhibit the invasive/metastatic bladder cancer development.

c-Myc has shown to be over expressed/mutated/translocated in a number of human cancers. It appears to play a key role in the development of B-cell lymphoma/leukemia/myeloid leukemia/lung adenocaricnoma. It also appears to play a role in metastasis, cancer stem cells (CSCs) proliferation, and reprogramming of differentiated cells into pluripotent stem cells. Interestingly, it has been shown to increase a number of oncogenic miRNAs, including miR-17–92 cluster [35]. It also appears to repress the expression of a number of key tumor suppressor miRNAs (discussed in detail later).

In this article, I will be discussing how the tumor suppressors p53, p73, and p63 regulate: (a) tumor progression, invasion, and metastasis through their target miRNAs; (b) c-myc through their target miRNAs/genes; (c) tumor suppressor miRNAs network; and (d) Epithelial to mesenchymal transition (EMT), migration, and CSCs proliferation.

2 The role of the "guardians of the genome and miRNAs" during tumor progression, invasion, and metastasis

p53, TA-p73, and TA-p63 have been shown to play an essential role in control of tumorigenesis, tumor progression, invasion, and metastasis. However, how they function

as metastasis/invasion suppressors is just beginning to be understood. It has recently been shown that p53-induced HDM2 promotes degradation of both Slug/Snai2 and Snail/Snai1, the negative regulators of the metastasis suppressor E-cadherin [36, 37]. Interestingly, mutant p53 expressing non-small lung carcinoma cells have lower levels of HDM2 and higher levels of Slug. This results in increased invasiveness and metastasis. This data suggests that p53, by promoting the degradation of both Slug and Snail, it could increase the expression of E-cadherin, and thereby inhibit metastasis (Fig. 1). Of interest, Snail1 has been shown to impair dentric cell function and thereby promotes induction of immune suppression (suppression of tumor-specific tumor-infiltrating lymphocytes) [38]. This data suggests that p53-induced downregulation of Snail may suppress both metastasis and immune suppression. Furthermore, Snail appears to inhibit the expression of the metastasis suppressors, such as Raf kinase inhibitory protein (RKIP)/PEBP1 and Tissue metalloproteinase inhibitor (TIMP3) [39, 40]. RKIP has been shown to inhibit Raf-1 (a downstream target of ras), MEK1, c-Myc, HGMA2, and lin-28 proteins and increase the tumor suppressor miRNA, let-7a/g processing [41]. This data suggests that p53, by degrading Snail, it could increase the expression of RKIP and let-7 (Fig. 1). Remarkably, this data suggests a possibility that RKIP/let-7, by negatively

regulating the transcriptional activators of HDM2 (the Ha-Ras-Raf-1-MEK-ERK signal transduction cascade), it could increase the expression of p53 [16, 41, 42; Boominathan, unpublished]. Interestingly, Trichostatin A, a histone deacetylase inhibitor and an inducer of E2F-1/TA-p73/p63 [43, 44], has been shown to induce RKIP expression, suggesting that Trichostatin-A and its derivatives could induce the *E2F-1-TA-p73/p63/p53-Snail-RKIP-c-myc-lin-28-let-7a/g-HMGA2-ras(Ha/N/K)*tumor/metastasis suppressor pathway.

Further, a number of studies have shown that p53-miRNAs—such as miR-34, miR-23, miR-107, and miR-145—play a key role in control of tumor progression, angiogenesis, and metastasis. First, p53-miR-34α has been shown to inhibit the expression of c-Met, a known promoter of migration and invasion of cancer cells [45]. Second, p53-miR-23 suppresses the expression of both c-Met and Urokinase-type plasminogen activator (an invasion and a migration promoter) [46]. Third, p53-miR-107 has recently been shown to suppress HIF-1β expression [47]. This in turn results in inhibition of tumor angiogenesis. Fourth, p53-miR-145 has shown to be poorly expressed in a number of cancers, including those of the lung, b-cell, liver, bladder, breast, and prostate. miR-145 suppresses Mucin expression and thereby inhibits invasion and lung metastasis in an experimental metastasis animal model [48]. In


Fig. 1 p53/TA-p73/p63 functions as a tumor/metastasis suppressor. The tumor suppressor p53/p73/p63 increases the expression of HDM2, which in turn promotes the degradation of metastasis initiators, SNAI1, and SNAI2. SNAI1/SNAI2 suppresses the expression of the metastasis/invasion/migration suppressors, such as RKIP, E-cadherin, TIMP3, PTEN, and ΔN-p63. SNAI1 also promotes immune suppression, while p53/p63/p73 opposes it. The metastasis suppressor RKIP inhibits the activation of Ras-Raf-MEK-HMGA2-SNAI1 signaling cascade by inhibiting the expression of c-Raf.

Additionally, it inhibits the expression of c-myc and its target gene Lin-28, and thereby increases the expression of the tumor suppressor miRNA, let-7 (a putative transcriptional target of p53/p63/p73). This in turn inhibits the expression of lin-28, c-myc, Ras and HMGA2. Downregulation of Ras-MEK signaling cascade may inhibit the expression of HDM2. This in turn will result in increased stability and activity of the tumor suppressor p53/p73/p63. Dicer1, a putative transcriptional target of p63/p73, suppresses invasion, and metastasis. *Dotted arrow* an indirect target

addition, it has been shown to suppress the expression of (a) BCL2/adenovirus E1B protein-interacting protein-3, a transcriptional repressor of apoptosis-inducing factor and a promoter of prostate cancer progression [49]; and (b) actin-binding protein, Fascin homologue 1, a promoter of bladder cancer and esophageal squamous cell carcinoma progression [50, 51]. Further, it has been shown that suppression of p63 in squamous cell lines resulted in upregulation of genes that promote mesenchymal morphology, motility, and invasion [52]. In support of this data, I have proposed previously that TA-p73/p63/p53, by inhibiting the expression of the negative regulators of E-cadherin—such as ZEB1/2, Snail1/2, Twist & Hey-1—through its target miRNAs, it could suppress to EMT, invasion and metastasis [53; Boominathan, unpublished]. Interestingly, ZEB1 has been shown to function as a negative regulator of the tumor suppressors TA-p73 and E-cadherin expression [54], suggesting that p53-miRs, by suppressing the ZEB1 expression, it could induce TA-p73 and E-cadherin. Furthermore, has been shown to suppress notch signaling and its downstream target Hey-1, suggesting that it may increase E-cadherin, and thereby suppress the EMT, and metastasis (TA-p73 ⊣ Notch-1/N1ICD→Hey-1/Slug/Snail1 ⊣ E-cadherin) [55, 56].

ΔN-p63—that lacks the NH2-terminus of full length TA-p63—has been touted to function as an oncogene. It has been shown to inhibit the functions of full-length p53/p63/p73. In addition, a number of studies provide correlative evidence for the conjecture that it may promote EMT, invasion, and metastasis:

(a) ΔNp63 ⊕⟷ STAT3 → Twist ⊣ E-cadherin ⊣ EMT; TA-p63γ ⊣ EGFR → STAT3 [57–59]
(b) ΔNp63 → Brachury → Slug ⊣ E-cadherin ⊣ EMT, Invasion and Migration [60, 61]
(c) ΔNp63 → HIF-1α → VEGF → Snail1 ⊣ E-cadherin; TA-p63 ⊣ HIF-1α [62–65]
(d) ΔNp63 → HIF-1α → Twist ⊣ INK4a/ARF/p53 [66]
(e) ΔNp63 ⊣ GSK3β ⊣ Snail1 ⊣ E-cadherin [67]

Paradoxically, ΔNp63 has shown to be lost in advanced invasive urothelial (bladder) carcinomas [4, 5, 68], suggesting a possibility that the presence of ΔNp63 may not support the invasion program in urothelial carcinomas. However, this data may prompt us to ask why it loses its expression if it can favor invasion and metastasis. Interestingly, ΔNp63 has been shown to downregulate N-cadherin (promotes mesenchymal phenotype), matrix-metalloproteinase-9 [69], and ERK activity/expression (ΔNp63 ⊣ ERK1/2 → Fra-1 → ZEB1/2 ⊣ E-cadherin), connoting that it could function as an invasion suppressor [69; Boominathan, unpublished]. Furthermore, it has been shown to induce inhibitor of differentiation-3 (ID-3; ΔNp63 → ID-3 ⊣ matrix-metalloproteinase-2 activity)

[70] and vitamin D receptor (induces E-cadherin) expression [71–75], suggesting that ΔNp63 could inhibit invasion and metastasis. In support of these data, it has previously been shown that: (a) the EMT/metastasis promoter protein Snail1 downregulates ΔNp63 and thereby promotes invasion of human squamous cell carcinoma (SCC) in in vitro [76]; (b) the myeloid/lung tumor suppressor CEBP-α induces the expression of ΔNp63 [76]; (c) the metastasis suppressor protein Bone morphogenetic protein-4 induces ΔNp63 expression [77]; (d) GATA3, a transcriptional target of ΔNp63/p63, induces the metastasis suppressors DLC1 and PAEP and thereby inhibits EMT, breast cancer dissemination and lung metastasis [78–81]; (e) IKKα, a transcriptional target of ΔNp63/TAp63, inhibits SCC [82–85]; and (f) p57Kip2, a transcriptional target of ΔNp63/p73, functions as a tumor suppressor in a number of human cancers [86] [Boominathan, submission in progress]. Of note, a weak transcriptional activator (ΔNp63) can become a strong transactivator when it is highly expressed, while a strong transcriptional activator (TA-p63) can become a weak transactivator when it is poorly expressed [expression pattern in most of the tissues: ΔN-p63>TA-p63 (e.g., keratinocytes: ΔNp63 (100): TA-p63/p53 (1) ratio; transcriptional activator efficiency: TA-p63>ΔN-p63)]. Nevertheless, a number of TA-p63/ΔN-p63-specific transcriptional targets have recently been identified. Evidently, ΔNp63 has been shown to transactivate cell adhesion molecules, such as BPAG1, EVL, PERP, ITA3-6, β4 INTG, and Laminin, suggesting that reduced ΔNp63 expression may decrease cell adhesion and increase migration, invasion, and metastasis [87]. ΔNp63 has also been shown to increase/transactivate the following tumor/metastasis suppressor genes: (a) p62DOK (lung cancer/leukemia tumor suppressor; 3.5-fold); (b) JunB (CML tumor suppressor; 3.7-fold); (c) PP2A-Aβ (mutations/deletions found in lung/colon/breast cancer; ninefold); (d) APC (colon cancer tumor suppressor; 4.3-fold); (e) AML/Runx1 (acute myeloid leukemia tumor suppressor; 5.2-fold); (f) HUGL (colon cancer tumor suppressor; 3.6-fold); (g) RASSF4 (hypermethylated in lung cancer; 2.5-fold); (h) AML-2/Runx3 (gastric/lung cancer tumor suppressor (ΔNp63 → Ets-1 → AML2 → Claudin1): expression is absent in small cell lung carcinoma (50%)/adenocarcinoma (50%)/squamous cell carcinoma(33.3%); hypermethylated in non-small cell lung carcinoma (25%)/adenocarcinoma (36.1%)); and (i) Claudin1 (a tight junction protein and a transcriptional target of ΔNp63; poorly expressed in metastatic breast cancers/tumor-initiating stem cells; inhibits progression, motility and invasivity of lung adenocarcinoma) [88–96]. These data suggest that ΔNp63 could function as an invasion or a metastasis/tumor suppressor by increasing the expression of a number of tumor/metastasis suppressor genes [Boominathan, in preparation].

Incongruously, TA-p63 isoforms, but not ΔNp63, have shown to be over expressed in primary mediastinal large (diffuse) B-cell lymphoma and in high-grade follicular lymphomas [97, 98]. In addition, TA-p63 expression appears to be frequently reactivated in human squamous cell carcinoma. Reactivation of TA-p63α in chemically induced skin carcinogenesis model accelerates tumor development and promotes EMT, spindle cell carcinomas, and lung metastasis [99], suggesting that its function may be altered in tumor microenvironment in such a way that it plays a pro-proliferative role in a cell type-dependent manner. Furthermore, TA-p63 has been shown to increase the Notch receptor ligand Jagged-1/2 (and its downstream target, Hes-1); and CDH3, suggesting that it could regulate the EMT and motility in a cell context-dependent manner [100–102]. Interestingly, TA-p63 has recently been shown to transactivate the E-cadherin suppressor ZEB1 in response to ischemic stress [103]. However, whether it will increase or decrease the ZEB1 expression in conditions that favor tumor progression remains ambiguous.

Considering TA-p63/p73 could induce apoptosis in a number of cell types suggests that its function is altered through post-translational modifications (or through interaction with oncoproteins) during tumor development or progression (so that it could support tumorigenesis or tumor growth). In addition, TA-p63/p73: (1) is induced in response to a number of DNA damaging agents, suggesting that it could play a role in protecting the genome integrity/stability; and (2) could function as a tumor suppressor by transactivating genes, such as JunB and AML/AML1/2 (other target genes/miRNAs discussed elsewhere in this article), in a cell context-dependent manner.

Further, ΔNp63 is predominantly expressed in most of the epithelial tissues compared to TA-p63, suggesting that it may function as a *guardian of epithelial integrity*. Of importance, most of the human cancers (carcinomas) are of epithelial origin. At this point, it may be germane to discuss the role of p53 and ΔNp63 in Notch signaling. Notch-1 functions as a tumor suppressor in skin/keratinocytes/SCC [104], while it functions as a proto-oncogene in lymphoid cells/acute T-cell lymphoblastic leukemia/lymphoma [105]. Intriguingly, p53 increases the transcription of Notch-1, while it decreases its expression at the post-transcriptional level through its target miR-34 [106, 107]. On the other hand, ΔNp63 suppresses its expression (and its target gene Hes-1-the negative regulator of the tumor suppressor PTEN) by directly binding to its promoter [108, 109], suggesting that ΔNp63 could play a metastasis/tumor suppressor role in cell context-dependent manner (e.g., skin, lymphoid cells/acute T-cell lymphoblastic leukemia/AML/lymphoma/lung adenocarcinoma). That is, ΔNp63, by inhibiting notch-1 signaling cascade [ΔNp63 ⊣ Notch-1 → Slug/Snail1/Hes1/c-myc ⊣ E-cadherin/PTEN ⊣ EMT, invasion &

metastasis], it can increase the expression of the invasion/tumor suppressor E-cadherin/PTEN and thereby inhibit migration, invasion, and metastasis [55, 108, 109]. Based on these data, I would like to propose that *ΔNp63 could function as an invasion or a metastasis/tumor suppressor* in a cell context-dependent manner. Nonetheless, one can confirm the hypothesis proposed here by (a) generating isoform/tissue specific (conditional) knockouts; and (b) crossing *ΔNp63+/−* mice with oncogenic/tumor/metastasis prone mouse models.

3 The p53/TA-p73/p63 ⟶ TRIM32 ⊣ c-myc ⊣ let-7 tumor suppressor pathway

It has recently been shown that the E3 ubiquitin ligase TRIM32 binds to c-Myc and thereby targets it for degradation [110, 111]. In addition, TRIM32 has been shown to bind to Argonaute 1 (a component of RNA-induced silencing complex), and thereby increases the efficiency of processing of miRNAs. It appears to enhance the processing of a group of miRNAs, including the tumor suppressor miRNAs, let-7, and miR-134 [112, 113]. Together, TRIM32, by promoting c-myc for degradation, it increases the expression of let-7 and miR-134, and thereby suppresses the proliferation and self-renewal of stem cell lineages [110–113].

p63 has been proposed to play a role in regulating asymmetric cell division [114]. However, how it regulates asymmetric cell division remains abstruse. Asymmetric cell division appears to be critical for stem cell self-renewal and differentiation. Deregulation of asymmetric cell division has been shown to result in cancer [115, 116]. Interestingly, TRIM32 has been shown to localize asymmetrically in one of the dividing progenitor neural cells. The progenitor cell that has higher levels of TRIM32 undergoes differentiation, while the other progenitor cell that has lower levels of TRIM32 retains its ability to undergo self-renewal [110, 111]. Based on this interesting observation, one may be tempted to propose that p63 by increasing the expression of TRIM32, it could regulate asymmetric cell division and differentiation of stem cells.

Further, I have recently proposed that TA-p73, by increasing the expression of miRNA, let-7, it could function as a tumor suppressor in lung cancer [117]. To find out whether let-7 cluster promoters contain p53/p63 responsive elements (p53/p63-REs), I have analyzed the let-7 cluster promoters using the TRASFAC bioinformatics tool. This analysis suggests that Let-7c contains three perfect p53-RE half-sites (−1980 to −1989: **aaacatgctt**; −3472 to −3481: **aaacttgttt**; −3615 to −3624: **gagcatgttc**) and three nearly perfect p53REs (−1348 to −1366: **(aatcatgcca)t(tatcgtgcca)**; −1594 to

−1623 (aaa**cgtg**tat)g(tgg**ctgg**ctt); −2583 to −2603: (tat**cgtg**ttt)t(ctt**ctcg**atc). Other let-7 cluster miRNAs also appear to contain several p53-REs, suggesting that let-7 cluster miRNAs could be transcriptional targets of p73/p63/p53 [117]. In support of this notion, it has been shown that activation of p53 results in increased expression of let-7c (2.7-fold), let-7e (2.1-fold), and let-7a (1.9-fold) [118].

To find out whether TA-p73 could also increase let-7 expression through TRIM32, I have analyzed the TRIM32 promoter sequence for potential p73/p63 binding sites. Remarkably, I have found a number of p63/p73-binding sites in human/mouse TRIM32 promoter [112], suggesting that it could be a transcriptional target of TA-p73/p63. Evidently, a microarray study suggests that TRIM32 expression is increased in response to TA-p73 expression [119]. This data further strengthens the notion that the TA-p73/p63, by increasing the expression of TRIM32, it could decrease the expression of c-myc in a cell context-dependent manner. Decreased expression of c-myc may result in increased processing of the tumor suppressor let-7 [113]. Together, TA-p73/p63, by decreasing the expression

of c-myc through TRIM32, it could increase the expression of let-7 and thereby function as a tumor suppressor and a key player in asymmetric cell division of stem cells (Fig. 2).

The let-7 miRNA cluster appears to be highly expressed in normal lungs, while a few members of the let-7 cluster appear to be down regulated in non-small cell lung cancer, suggesting that they could function as tumor suppressors in lung cancer [120–122]. A recent microarray data suggests that let-7 expression downregulates mRNAs, such as *CCNA2, CDC34, ASK, ARKA, ARKAB, E2F5-8, PLAGL1 and 2, Dicer1, GMNN, NRAS (possibly K-ras/Ha-ras), HMGA2, Lin28B, CDC2, CCNB1, CCNE2, CCNF, CCNJ, SKP2, CKS1B, CDCA1-3;5,7–8; RRM1-2, CDC6, CDC45L, CDT1, ORC1L and ORC6L, MCM2/3/4/5/6/7/8/10, RFC2/3/4/5, MAD2L1, and CDC23* (Fig. 2) [123], that play a role in proliferation, signal transduction, transcription, replication, cell cycle, and metastasis. This data suggests that TA-p73, by increasing the expression of let-7, it could decrease the expression of these proteins and thereby function as a tumor suppressor in lung cancer (Fig. 2).


Fig. 2 How TA-p73/p63/p53 induces the expression of let-7. The tumor suppressor TA-p73/p63/p53 increases the expression of let-7, which in turn suppresses the expression of genes involved in cell cycle, cell proliferation, replication, oncogenic kinases, and transcription factors. Let-7-dependent downregulation of these proteins may result in upregulation of tumor suppressor genes (let-7; p53/TA-p73/p63; INK4a/b/ARF; CDH1; PTEN; CDKN1 a/b/c; c-myc-suppressed tumor suppressor miRNAs/genes). *Dotted arrow* denotes a putative target

In addition, TA-p73, by regulating the expression of BUB1, BUB1B/BUBR1 [spindle assembly proteins], and CDC20 through let-7 [123], it could inhibit the function of anaphase-promoting complex and thereby promote proper alignment of chromosomes during mitosis/meiosis to maintain genomic integrity. Of interest, BUBR1 is also targeted by p53/p73/p63-miRs, such as miR-34c-3p and miR-130a/b* (Target scan; *-putative target) [113]. Furthermore, BUBR1 has been shown to function as a negative regulator of INK4a expression [124], suggesting that p73/p63/p53-miRs, by regulating BUBR1 expression, it could regulate INK4a. Intriguingly, crossing BUBR1 hypomorphic mice with INK4a−/− mice predisposes them to lung adenocarcinoma, suggesting that both BUBR1 and INK4a co-operate in the inhibition of adenocarcinoma development [35]. Remarkably, TA-p73−/−, E2F-1−/−, and p63+/− mice are also prone to adenocarcinoma of the lung, suggesting a lung specific tumor suppressor network involving E2F1, TA-p73, p63, let-7, BUBR1, and INK4a proteins [1, 19]. This notion is in concordance with the tumor-suppressor pathway-E2F1-TA-p73-JunB-INK4a/BRCA-that I have previously proposed [1]. Of interest, INK4a promoter is inactivated by hypermethylation in metastatic lung cancers [125, 126]. Further, (a) p63/p73's putative target gene Dicer1 has been proposed to function as a metastasis suppressor [113] (Fig. 1); and (b) p73/p63's target gene BRCA1/2 has been shown to promote kinetochore localization of BUB1 and BUBR1 and thereby increases their mitotic checkpoint function [1, 127]. Therefore, it would be interesting to cross *TA-p73+/−/TA-p63+/−/p63+/−/p73+/−/p73−/−* mice with *E2F1+/−, JunB+/−, INK4a+/−, INK4b+/−, PTEN+/−, Dicer+/−, BUBR1+/−, TSC+/−, and BRCA-1/2+/−* mice to determine whether they synergize/cooperate in tumor suppression. Together, TA-p73, by promoting genomic integrity/stability through let-7, it could function as a tumor suppressor gene.

Further, let-7 promoter contains PAX-5 responsive elements, suggesting a possibility that PAX5 could regulate its expression. Pax5 has recently been shown to be mutated [31%] in acute lymphoblastic leukemia [128], indicating that it could function as a tumor suppressor gene. Of interest, Pax5 promoter contains a number of p63-REs [−149 to −173: (ggc**cgcg**acc)c c c a a (gcg**catg**tct); −807 to −829: (gaa**caggg**ag)g g g (agg**cttg**agt); −2494 to −2515: (gca**catg**tat)c t (gtg**cttg**caa); −2526 to −2548: (tct**ctgg**cgg)t g t (ctg**cgtg**tgt); −4024 to −4045: (gcg**ctgg**aaa)c t (agt**cgtg**gaa); −4052 to −4073: (aca**cttg**acg)t c (tac**catg**tgt); −5865 to −5895: (gta**catg**agt)(cta**cgtg**caa)a(ttg**catg**aga); −6473 to −6495: (gag**catg**acc)c c a (ccc**cttg**cca); −8921 to −8940: (ggg**catg**gtg)(gct**catg**cca)], suggesting that it could be a direct transcriptional target of TA-p63. In support of this notion, p63 has been shown to bind to the Pax5 promoter [129], suggesting that it may increase let-7 expression through Pax5, and thereby it could function as a tumor suppressor gene. Interestingly, let-7 may also increase p63 protein level by suppressing the expression of its negative regulator RNPC1 (context percentile score: 61–63), and thereby share a positive feedback loop (Target scan) [130] (Fig. 2). The Pax-5 promoter also contains activator protein-1 responsive elements [−6567 to −6573: tgactca; −8017 to −8923: tgaatca], suggesting that TA-p73 could also increase the expression of Pax-5 through its ability to increase JunB/activator protein-1 responsive element containing promoters [1, 131].

As discussed, ΔN-p63 binds to the tumor suppressor p53/TA-p73/p63 protein and thereby inhibits its functions. miR-203 has recently been shown to negatively regulate the expression of ΔN-p63 [132], suggesting that it could increase the functions of p53/TA-p73/p63. Interestingly, miR-203 promoter also contains Pax5 responsive elements, suggesting that TA-p63 could downregulate the expression of ΔN-p63 by regulating the Pax5 → miR-203 pathway. In addition, miR-203 could be a direct transcriptional target of TA-p73/p53/p63 [53], as it appears to contain a number of p53/p63-REs [−171 to −197: (cgg**ctgg**gat)cccccag(cgc**cagg**cga); −200 to −226: (cag**cgag**gac)g c g g c g (ggg**ctgg**gct); −406 to −442: (gag**caggt**cc)ccg(ggc**cgtg**gag)gatc(agt**cgcg**gga); −558 to −600: (gcc**cgag**cac)ccccggccc(aga**cgag**acg)gttc(ggg**cgtg**gcc); −926 to −949: (gag**cgag**gct)cag(gcc**cttg**ctg); −2552 to −2582: (aga**caggc**tt)gggagc(gtt**cgtg**tcc)tg(cgc**cgcg**ttg); −4566 to −4587: (gga**cgtg**act)t(ggc**caag**tgg)] [53]. This data further strengthens the notion that p53/TA-p63/p73 could downregulate the expression of ΔN-p63 by inducing the expression of miR-203 in a cell context-dependent manner (e.g., DNA damage response). Further, miR-203 appears to suppress the expression of Snail1*/Slug* (N-cadherin*, TGFβ2*, Src*, and VEGFA*), which has been shown to inhibit the expression of the metastatic suppressor E-cadherin/PTEN [53; Target scan; *-predicted]. Downregulation of E-cadherin has been shown to promote EMT, invasion, and metastasis. Together, TA-p73/p53/p63-dependent miR-203 expression may result in downregulation of Snail1/Slug and increased expression of E-cadherin [*TA-p73/p53/p63-JunB-miR-203-Snail1/Slug/E-cadherin*]. This in turn will result in inhibition of metastasis. Correspondingly, both TA-p73 and TA-p63 have recently been predicted to function as negative regulators of EMT and metastasis by suppressing the expression of ZEB1/2 [53, 54]. Interestingly, knockdown of ZEB1 has been shown to result in increased expression of the tumor suppressor INK4B, which in turn promotes senescence [54]. This data suggests that TA-p73 and TA-p63, by suppressing ZEB1 expression, they could increase the expression of CDKN1A and INK4B and thereby promote senescence [53]. Of interest, miR-203 is predicted

to target the expression of the negative regulator of INK4a/ARF, BMI [TA-p73/p53/p63-JunB-miR-203-BMI-INK4a/ARF] [Target scan].

Further, let-7-dependent downregulation of S-phase kinase associated kinase (Skp-2) may: (a) promote senescence by inducing the expression of Atf-4, CDKN1A, and CDKN1B/p27Kip1 [123, 133]; and (b) inhibit the c-Myc-Skp2-Miz1-p300-RhoA cascade and thereby inhibit cell migration, invasion, and metastasis [134] (Fig. 4). Interestingly, p27Kip1 has been shown to inhibit RhoA activity, suggesting that the let-7-Skp-2-p27Kip1 pathway may inhibit cell cycle progression by inhibiting cyclin-CDKs. Remarkably, inhibition of the RhoA-mammalian diaphanous 1 (mDIA) pathway upregulates the expression of CDKN1-A and -B, while inhibition of the RhoA-ROCK pathway induces the expression of INK4-A, -B, -C, and -D [135] (Fig. 4).

CKS1B, an important regulator of Skp-2, also appears to be negatively regulated by let-7 (miR-145/194*{*-a putative transcriptional target of p53} Target scan; Fig. 2). Let-7-dependent downregulation of Skp2 and CKS1B (transcriptional targets of c-myc) may result in upregulation of tumor suppressors such as p53, p27Kip1, CDKN1A, p57kip2, and p130 [136, 137]. Increased expression of p27Kip1 may impair Stathmin (a microtubule destabilizing protein) activity and thereby inhibit sarcoma progression, mesenchymal cell motility, and metastasis [138]. Of relevance, p63/p73/p53 appears to inhibit EMT and sarcoma progression/development [53]. Importantly, loss of CKS1B has been shown to inhibit c-myc-induced lymphomagenesis [139]. Furthermore, the tumor suppressor p130 has been shown to inhibit k-ras induced lung carcinoma, suggesting that the let-7-Skp2-p130 tumor suppressor pathway may inhibit lung carcinoma [140]. Together, the p53/p73/p63-let-7-c-myc/Skp-2/CKS1B/CDK1-p130/RhoA-CDKN1-A/-B/p57Kip2/INK4-a,-b,c,-d pathway may promote senescence and inhibit tumorigenesis, motility, invasion, and metastasis.

Yet another target that has shown to be suppressed by let-7 is CDC6 [123]. CDC6 is over expressed in a number of human cancers, including lung carcinomas. It appears to bind to repressor elements present in INK4-ARF gene locus (containing INK4B/A and ARF) and thereby inhibits its expression [141]. Based on this data, I have proposed previously that suppression of CDC6 in human cancers may result in increased expression of the tumor suppressors INK4a, INK4b, and ARF [Boominathan, unpublished]. Remarkably, let-7, by stifling the expression of CDC6 [123], it could increase the expression of the tumor suppressors INK4a, INK4b, and ARF (Fig. 2). Evidently, CDKN2B/INK4B, a component of the INK4A-ARF locus (inhibits CDK4/6; deleted/hypermethylated in a number of cancers including transitional cell carcinoma), has shown to be induced by let-7 [123]. In addition, it is possible that the tumor suppressor p53/TA-p73/p63, by suppressing the

expression of CDC6 through let-7, it could induce the expression of INK4a, INK4b, and ARF.

Further, expression of let-7 has been shown to increase p53-inducible ribonucleotide reductase (a transcriptional target of p53 and a metastasis suppressor) and CycG2 (a transcriptional target of TA-p63/p73 and a metastasis suppressor) [123, 142], connoting that it suppresses the expression of repressors of p53/p63/p73 and thereby induces the expression of p53/p63/p73. This in turn induces the expression of its transcriptional targets, such as Cyc G2 (p63/p73) and p53-inducible ribonucleotide reductase (Fig. 2). Furthermore, let-7 has been shown to increase the expression of EIF2C2/Ago2 (promotes the miRNA processing in a dicer-dependent/independent manner), and the Myc antagonist, max interacting protein 1 (MXI1) [123], suggesting that let-7 could promote the efficiency of miRNA/small RNA processing. Additionally, by increasing the expression of the MXI1, it could suppress c-Myc-dependent oncogenic functions (discussed in detail later on). These data together suggest an intriguing possibility that both TA-p73/p63/p53 and let-7 could share a regulatory feedback loop (Fig. 2) [113].

Over expression of LIN28, EGFR, k-ras, c-Myc, and HMGA2 has been shown to result in lung adenocarcinoma/CML [143]. In particular, LIN28 appears to be over expressed in both BC-CML (42.8%) and accelerated-CML (40%) than CP-CML. HMGA2 also appears to be over expressed in CML [143]. Interestingly, let-7 has been shown to repress the expression of LIN28, k-ras, c-Myc, and HMGA2 mRNAs [120, 144], suggesting that TA-p73/p63, by increasing the expression of let-7, it could suppress the expression of LIN-28, HMGA2, k-ras, and c-Myc proteins (Fig. 3). The let 7-mediated repression of HMGA2 will result in upregulation of the tumor suppressors p14ARF and INK4a, as HMGA2 has previously been shown to suppress the expression of p14ARF and INK4a [145] (Fig. 3). Additionally, E-cadherin will be upregulated, as HMGA2 has been shown to increase the expression of E-cadherin's negative regulators, such as Snail, Slug, and Twist [146]. Thus, these data suggest that TA-p73/p63, by suppressing the expression of these key oncogenic proteins, it could function as a tumor suppressor in lung adenocarcinoma/CML.

Further, TA-p63γ has been shown to suppress the expression of EGFR [58]. Evidently, a recent study suggests that inhibition of EGFR results in downregulation of TWIST, a known suppressor of E-cadherin expression and a promoter of EMT (Fig. 4) [53, 59]. These data suggest a possibility that TA-p63γ/p73β, by inhibiting the expression of oncogenic EGFR, it could inhibit the TWIST expression, and thereby increase the E-cadherin expression [53, 147]. This in turn will result in inhibition of EMT. Remarkably, let-7 has shown to be downregulated in CSCs/

Fig. 3 How p53/TA-p73/p63 increases the expression of c-myc-suppressed miRNAs (let-7, miR-29, miR-15/16, miR-26, miR-34, miR-30, and miR-146). Increased expression of let-7 suppresses the expression of key oncogenes (k-ras; HMGA2; EGFR) and stem cell factors (Lin-28; Log2/6; 4–12) that promote tumorigenesis and cancer stem cell proliferation. By negatively regulating HMGA2, let-7 increases the expression of INK4a/ARF. One of the c-myc-suppressed miRNAs, miR-29 suppresses DNMTs that are known to hypermethylate tumor suppressor gene/miRNA's promoters, including TA-p73, miR-148 and miR-34. miR-148 appears to target HIF-2α, a positive regulator of stem cell factors Oct-4, Sox-2, Klf-4, Nanog, c-mys, and Twist. The role of other c-myc suppressed miRNAs (miR-15/16, miR-26, miR-34, miR-30, and miR-146) in the inhibition of tumorigenesis is described in the text. Both c-myc and let-7 oppose each other's expression and share a double negative feedback loop. *Dotted arrow* a putative target

tumor-initiating breast cancer cells, suggesting that it could negatively regulate the proliferation of CSCs [16, 144, 145]. Furthermore, let-7 suppresses the expression of stem cell factors, such as Lin-28 and Log-2/6; 4; 5–12, and thereby inhibits the generation of CSCs (Fig. 3) [148, 149]. Of importance, Lin-28 is one of the components required for the generation of the induced pluripotent stem cells from differentiated cells [150]. Together, TA-p73/p63/p53, by increasing the expression of let-7 (*guardian against pluripotency and cancer progression*) [148], it could inhibit EMT, metastasis, and CSCs generation.

4 The p53/TA-p73/p63 ⟶ miR-145/FBXW7 ⊣ c-myc tumor suppressor pathway

We have showed previously that the tumor suppressor p53 suppresses the expression of c-myc [Boominathan & Rotter, unpublished]. However, how it suppresses or degrades c-myc remained elusive. FBXW7, an F-box subunit of SCF-type ubiquitin ligase complex and a transcriptional target of p53/E2F-1, has shown to be mutated in 30% of acute T-cell lymphoblastic leukemia/lymphoma [151, 152]. It appears to degrade c-myc/N-myc, Notch, mTOR, ΔN-p63, c-Jun, and Cyc E, suggesting that p53 could decrease the expression of c-myc, Notch, mTOR, c-Jun, and Cyc-E through FBXW7 [153]. Interestingly, both *FBXW7+/−* and *E2F1/2+/−* (*p53 +/−/TAp73+/−/TAp63+/−*) mice are prone to leukemia/lymphoma [154; 1 (references therein)], suggesting that they may co-operate in tumor suppression. In addition, like p63, FBXW7 appears to play a role in stem cell maintenance [113, 155]. Together, these data suggest a tumor suppressor network involving *E2F1/2-p73-ARF-p53/p63-FBW7-Notch-c-myc-N-myc-mTOR-CycE proteins*. This tumor suppressor network could play a role in the inhibition of leukemia/lymphoma development.

Fig. 4 How TA-p73, TA-p63, and p53 inhibit EMT, invasion and metastasis. p53/TA-p73/p63 negatively regulates the metastasis initiators (ZEB1 and ZEB2) and the EMT through its target miRs (miR-145, miR-192, miR-29, miR-215, and miR-23). Downregulation of ZEB1 and ZEB2 results in upregulation of the metastasis suppressors E-cadherin, TA-p73, and INK4B. c-Myc increases the expression of genes—such as Skp-2 [RhoA-mDIA/ROCK], HIF-2α [Oct-4-Sox-2-Klf4-Nanog; Twist] and lin-28 [let-7-log2/6; log4-12]—that promote metastasis and CSCs proliferation. c-Myc-dependent upregulation of Skp-2/BMI-1 downregulates CDK inhibitors. HIF-1α increases the expression of Twist and thereby activates the metastasis cascade miR-10B-HB-10D-RhoC. Together, p53/TA-p73/p63 suppresses c-myc, HIFs, and ZEB1/2 expression through its target miRs and thereby inhibits EMT, CSCs, invasion, and metastasis

Further, a recent study showed that p53 binds to miR-145 promoter and increases its expression, which in turn, targets c-Myc for degradation [156]. Nevertheless, miR-145 also appears to be induced in a p53-independent manner [156], suggesting that p53 homologue, TA-p73/p63 could increase its expression. Interestingly, miR-145 expression has shown to be suppressed in lung cancer [157]. Remarkably, reintroduction of miR-145 suppresses the growth of lung cancer in mice [157], suggesting that the TA-p73/p63-miR-145 pathway may mediate tumor suppression in lung cancer. Of relevance, the E2F-1/2-TA-p73-JunB-INK4a tumor suppressor pathway has previously been proposed to inhibit leukemia/lymphoma and lung cancer [1]. This notion is supported by previous studies that showed both E2F-1−/− and TA-p73−/− mice are prone to lung adenocarcinoma [19, 158]. Remarkably, miR-145 appears to inhibit the expression of factors—Oct-4, Sox-2, c-myc, fibronectin (FN1)*, CDH2*, Hey-1*, and PTK2*—required for the generation of CSCs/Stem cell self-renewal/

reprogramming/migration/metastasis (Fig. 4) [112; Target scan; *-predicted]. Together, it appears that induction of the tumor suppressor TA-p73/p63/p53-miR-145-c-myc pathway may inhibit lung cancer development, progression, metastasis, and CSCs.

c-Myc has recently been shown to increase the transcription of Lin-28 [159], which in turn, inhibits the processing of let-7. This data suggests that TA-p73/p63/p53, by downregulating the expression of c-Myc through miR-145, it could increase the expression of the lung cancer tumor suppressor let-7 (Fig. 4). This data further suggests that in the absence of TA-p73/p63/p53, c-Myc expression could be augmented. This in turn will result in increased expression of its oncogenic target miRNAs, such as miR-17–92; 106 cluster [160] (Fig. 5). Increased expression of miR-17–92 cluster may suppress the expression of metastasis/invasion/migration/tumor suppressors, such as PTEN, E2F-1/2, CDKN1A, BIM, AML-1/2*, p38α* (inhibits the proliferation of branchioalveolar stem cells, the putative

Fig. 5 The p53/TAp73/p63-dependent degradation of c-myc results in downregulation of oncogenic miRNAs and activation of tumor/metastasis suppressor genes. p53/TAp73/p63 suppresses c-myc through its protein-coding (PTEN, TRIM32, and FBXW7) and non-coding (miR-145, let-7, and miR-34) target genes. c-Myc increases the expression of both its protein-coding (Skp-2) and non-coding (miR-17–92, miR-221/222, and miR-9) targets to suppress the expression of tumor suppressor genes. *Asterisks* denotes a putative target

initiators of adenocarcinoma of the lung), *DMTF1*, TSC1*, DOK2*, CDKN1C** (miR-92b), *SMAD2*, BRCA1**, Retinoblastoma (*p105**)/*p107*/p130, PPP2R2A*, TSP-1*, TA-p63*/ΔN-p63-α/β* (miR-92b), *CycG2*, DEC2*, RhoB*, BRMS-1*, MEK4*, CD82/Kai1*, DLC1*, CTGF*, CLU*, SIK1*, HIC1*, and Dicer1** (Fig. 5), and thereby promote tumorigenesis, EMT, angiogenesis, invasion, metastasis, and CSCs proliferation [35, 160–162; http://www.targetscan.org// http://mami.med.harvard.edu//http://diana.cslab.ece.ntua.gr/ microT/; Boominathan, in preparation; *-predicted].

Remarkably, miR-17–92 cluster appears to inhibit a number of components—*p63/p73-CDKN1C/CDKN1A/ CycG2/DEC2/AML1/DOK2/p105/CD82/Dicer1/DMTF*—within the p63/p73-tumor suppressor pathway, suggesting the conserved nature of miR-17–92 cluster to target the p63/p73-tumor suppressor pathway [Boominathan, unpublished]. As discussed, TA-p63/p73 has been shown to function as a metastasis suppressor by inducing the expression of CycG2 and DEC2 [142]. This data suggests a possibility that increased expression of c-myc and its target gene miR-17–92 may suppress TA-p63/p73's ability to function as a metastasis suppressor. Additionally, increased expression of miR-17~92 will result in downregulation of the tumor suppressor PTEN protein [162]. This in turn may result in increased expression of p53 and PTEN loss-dependent senescence in a cell context-dependent manner [163]. Interestingly, a number of p53-miRs, such as miR-23, miR-26, miR-29, miR-25, miR-32, miR-92, miR-200, and miR-130*, appear to target the expression of PTEN (Target scan; Boominathan, unpublished; *-putative). Further, anti-sense oligonucleotides that suppress miR-17–92 expression promote apoptosis of lung

cancer cells [164], indicating that TA-p73/p63/p53, by suppressing the expression of c-Myc, it could downregulate the expression of miR-17-5p. In addition, miR-17-5p appears to be over expressed in a number of cancers, including B-cell lymphoma and myeloid leukemia. Increased expression of miR17–92 may result in downregulation of the *E2F-1-p73/p63-AML-1/JunB-ARF/INK4a* and the *PTEN-PML-PP2A/p73-Foxo3a/BIM/FasL/ CDKN1b* tumor suppressor pathways; and upregulation of β-catenin expression, as E2F-1 has recently been shown to suppress the expression of β-catenin [165; Target scan]. Increased expression of β-catenin may contribute to the generation of CML-specific stem cells [166, 167]. Interestingly, miR-17–92 cluster appears to target the expression of the 1p36 tumor suppressor and the positive regulator of INK4a/ARF, CHD5 (1p.36.31) [target scan], suggesting that tumors that over express miR-17–92 may downregulate INK4a/ARF levels [Boominathan, in preparation]. This data further suggests that p53/p73/p63/let-7/miR-34/miR-145, by suppressing the expression of c-myc, it could downregulate the expression of miR-17–92. This in turn will result in increased expression of the 1p36 tumor suppressor CHD5. Remarkably, p53 has recently been shown to suppress the expression of miR-17–92 cluster in response to hypoxia [168], suggesting that p53/TA-p73/p63, by suppressing the expression of miR-17–92 cluster, it could increase the expression of a number of tumor suppressor genes (Fig. 5). When this article was about to be submitted for review, it has been shown that the upstream activator of p73, E2F-1 increases the expression of let-7 [169]. This data suggests an interesting possibility that E2F-1 may also increase the expression of let-7

Fig. 6 The p53/TA-p73/p63-dependent tumor suppressor miRNAs network. An integrated view of how p53/TA-p73/p63-dependent tumor suppressor miRNAs' network activates tumor suppressor genes and thereby inhibits EMT, CSCs, migration, invasion, and metastasis. *Dotted arrow* denotes a putative target

through p73. Interestingly, c-myc is also a transcriptional target of E2F-1, suggesting a tumor suppressor network involving *E2F-1/2, p73, c-myc, and let-7*. Together, high levels of c-myc may result in increased expression of miR-17–92 cluster in cancer cells. This in turn may degrade the transcriptional activator of p73/let-7, E2F-1 and thereby disrupt the *E2F-1/2-p73/let-7-JunB-INK4a/ARF/p53/PTEN* tumor suppressor network in Myc-induced B-cell lymphomas/lung cancer/glioblastoma [170].

Further, E2F-2 has recently been shown to inhibit c-myc induced lymphomagenesis, suggesting that the *E2F-2-p73-let-7-c-myc* pathway may suppress lymphomagenesis [171]. Evidently, either E2F2 (1p.36) or p73 (1p.36.3) appears to be poorly expressed in a number of haematopoietic (non-Hodgkin lymphoma {Burkitt lymphoma, and diffused large B-cell lymphoma}, natural killer cell lymphoma, and acute lymphoblastic lymphoma) malignancies [1], non-small lung carcinoma, and neuroblastoma. Additionally, E2F-2 gene is deleted in neuroblastoma, breast cancer, and pheochromoc-

tyoma, while E2F-1 expression is decreased in oral SCC, colon cancer, and gastric adenocarcinoma [2]. Insulin-like growth factor 2 mRNA binding protein 1 has been shown to bind to c-myc mRNA, and thereby promotes its stability [113]. Interestingly, let-7 appears to suppress its expression [113]. This data suggests that let-7 could regulate c-myc stability through different mechanisms. Together, these studies provide mechanistic insights into p53, TA-p73, and p63's ability to function as tumor/metastatic suppressors.

Further, it has been shown that high levels of c-Myc bind to the tumor suppressor miRNAs, such as *let-7a/d/g, miR-29a/b/c, miR-15/16a, miR-34, miR-26a/b, miR-30b/c/d/e, miR-150, miR-146a, and miR-22*, and thereby suppress their expression [172] (Fig. 3). Importantly, c-myc-mediated repression of these tumor suppressor miRNAs in mice promotes B-cell lymphoma growth [172]. In addition, it has recently been shown that c-myc suppresses the expression of miR-23 [173]. Interestingly, c-Myc has been

shown to interact with p73α protein and thereby suppresses its transcriptional activity [174]. Of note, p73α has been shown to suppress MYCN mRNA stability [175]. However, how it suppresses MYCN remained elusive. Here I propose that p73α may decrease MYCN mRNA stability through its ability to increase p53-miRNAs, such as let-7, miR-34, miR-200, miR-145, miR-29, and miR-101 [Target scan; Boominathan, unpublished]. Remarkably, c-Myc-inactivation has been shown to suppress tumorigenesis in a wild-type p53-dependent manner [176], suggesting that c-myc inactivation activates a p53-dependent tumor regression [176]. Together, these data suggest that p53/TA-p73/p63, by increasing the expression of miR-145/34/let-7/TRIM32/FBXW7/PTEN, it could suppress the expression of c-myc. This in turn will result in increased expression of the c-myc-suppressed tumor suppressor miRNAs (*miR-29a/b/c, miR-15/16a, miR-34, miR-26a/b, miR-30b/c/d/e, and miR-146a*) and inhibition of tumorigenesis, invasion, motility, angiogenesis, CSCs, and metastasis [172, 173] (Figs. 3, 4, and 5).

5 The p53/TA-p73/p63 ⊣ c-myc ⊣ miR-29 tumor suppressor pathway

The tumor suppressor miR-29, which appears to function as a tumor suppressor in lung cancer, chronic lymphocytic leukemia (CLL), AML, rhabdomyosarcoma and nasopharyngeal carcinoma, has been shown to negatively regulate the expression of DNA methyl transferases, such as DNMT3a, DNMT3b, and DNMT1 (Figs. 3, 4, 5, and 6) [177, 178]. Correspondingly, its expression is downregulated in a number of cancers, including lung cancer, CLL, AML, rhabidomyosarcoma, and nasopharyngeal carcinoma. Remarkably, ectopic expression of miR-29 has been shown to increase the expression of the tumor suppressors FHIT and WWOX (inhibits growth of lung cancer *in vitro* and *in vivo*) and thereby reduces the proliferation of lung cancer cells [178]. miR-29 has also been shown to suppress the expression of B/T-cell oncogene, Tcl-1/Mcl-1, which is over expressed in CLL/AML. Interestingly, miR-29 appears to target the expression of c-fos [Target scan], which has been shown to be required for the increased self-renewal of hematopoietic stem cells (HSCs) [179]. The fact that deregulation of HSCs/stem cell self-renewal results in leukemia suggests that miR-29 could play a role in the inhibition of leukemia development. Interestingly, miR-29 is predicted to target the expression of Inhibitor of DNA binding-1 [Target scan], the negative target of ΔN-p63 [−2.2-fold] [96]. Over expression of Inhibitor of differentiation-1 appears to (a) promote oncogenesis in a number of cancers, including T-cell lymphoma, oral SCC, AML, breast, prostate, and bladder cancer; and (b) suppress the expression of

CDKN1A, INK4a, and PTEN proteins. Furthermore, miR-29's promoter has shown to be epigenetically silenced (Figs. 3, 4, 5, and 6) by activated NFKB-YY1 circuit in rhabdomyosarcoma; and reintroduction of miR-29 suppressed the growth of rhabdomyosarcoma in mice [180], indicating that it functions as a tumor suppressor gene in rhabdomyosarcoma. This data suggests a possibility that miR-29, by negatively regulating DNMTs, it could increase the expression of the tumor suppressor TA-p73, as its promoter is hypermethylated (silenced) in several cancers, including acute lymphoblastic leukemia, AML, natural killer cell lymphoma, B-cell lymphoma, and lung cancer [1]. Remarkably, miR-29 has recently been shown to increase the p53 protein levels by suppressing the expression of p85 [the regulatory subunit of PI3K] and CDC42 [181]. Of importance, miR-29 promoter contains a number of p53REs (Boominathan, unpublished observation), suggesting a possibility that it could be directly regulated by p53, TA-p73, and TA-p63. In support of this notion, it has been shown that activation of p53 increases the expression of miR-29a (2.8-fold) [118, 182].

Further, it has been shown that treatment of lymph node metastatic cancer cell line with a DNMTs inhibitor increases the expression of miR-148, and miR-34 [183], suggesting that their expression is silenced and they can be reactivated to inhibit metastasis. This data also suggests a possibility that miR-29, by downregulating the expression of DNMTs, it could increase the expression of miR-148, and miR-34 (Fig. 3). This in turn will result in decreased expression of their oncogenic target mRNAs, including HIF-2α, and E2F-3 [Target scan] (Fig. 3). Decreased expression of HIF-2α may result in downregulation of its transcriptional targets, such as Oct-4, Sox2, Lin-28, c-Myc (known to play a role in the generation of CSCs), klf-4 (required for the generation of iPS cells), and Twist (required for metastasis progression; Fig. 3) [Boominathan, submitted], and inhibition of tumorigenesis, CSCs proliferation, invasion, and metastasis (Fig. 3). Interestingly, miR-148 appears to suppress the expression of DNMT3a/b and DNMT1 [184; Target scan; Boominathan, submitted], suggesting a double negative feedback loop (Fig. 3). Finally, miR-148 has shown to be downregulated in hypoxic tumors, suggesting a possibility that DNMT-1/3b will be upregulated in these tumors [Boominathan, submitted]. This in turn could result in inactivation of key tumor suppressor genes/miRNAs, including TA-p73, INK4a, PTEN, BRCA1, and miR-34 (Fig. 3).

Next, miR-29 is predicted to target the expression of the metastatic promoter SMAD1 interacting protein, *SIP1/ZEB2* and the negative regulator of p53, p73, LKB1, miR-134, and FoxO3a, *SIRT1* (Fig. 6; Target scan). Interestingly, miR-192, a transcriptional target of p53 (possibly, TA-p73/p63), also appears to inhibit the SIP1 expression [185–187]. p53/TA-p73/p63, by increasing the expression

of miR-192/miR-29, it could suppress the expression of SIP-1. This in turn could result in inhibition of EMT and metastasis (Fig. 4). Further, it has been shown that the negative regulator of EMT and the positive regulator of epithelial phenotype, miR-200 represses the expression of ZEB1 (Fig. 4) [188], which functions as a negative regulator of TA-p73, INK4B, CDKN1A, and E-cadherin and a positive regulator of EMT (Fig. 4). Interestingly, it has recently been reported that ZEB1 represses the expression of miR-200, suggesting that both ZEB1 and miR-200 could share a double negative feedback loop [35] (Fig. 4). miR-200 also appears to suppress the expression of SIP1/ZEB2, which in turn suppresses the expression of miR-200, suggesting that both ZEB2 and miR-200 could share a double negative feedback loop [189] (Fig. 4). Additionally, miR-200 is predicted to target the expression of DNMT3b (Fig. 6) [Target scan]. Considering the fact that TA-p73/INK4a/PTEN/miR-34 promoter is hypermethylated in a number of human cancers, it is tempting to speculate that reintroduction of miR-200/29 in cancer cells may reactivate its expression by suppressing the expression of DNMTs. Remarkably, miR-200 promoter appears to contain a number of p53REs, suggesting that it could be a transcriptional target of p53/TA-p63/p73 [53]. This data further suggests that p53/TA-p73/p63, by increasing the expression of miR-200, it could inhibit the suppressor of TA-p73/E-cadherin/INK4B/CDKN1A expression, ZEB1 (Fig. 4). Taken together, these interesting data from a number of laboratories buttress the notion that increasing the expression of miR-200 in human cancers may increase the expression of the tumor suppressors TA-p73, INK4B, and E-cadherin, and thereby prevent invasion , metastasis and CSCs proliferation [Boominathan, unpublished].

In support of the notion that miR-29 functions as a negative regulator of metastasis, it has recently been shown to suppress the expression of tristerapolin, which functions as a negative regulator of EMT, metastasis, and epithelial polarity [190]. Furthermore, miR-29 has been shown to inhibit the expression of extracellular matrix proteins, such as collagens, and laminin γ (PTP4A1*—a positive regulator of metalloproteinase enzymes 2/9{promotes CLL survival}), and thereby it functions as a suppressor of metastasis in nasopharyngeal carcinoma [191; Target scan;-*predicted]. AIB1/SCR3, a transcriptional co-activator of PEA3, E2F-1, AP-1 and nuclear receptors, has shown to be over expressed in 30% of human breast cancer. It synergizes with PEA3 in increasing the expression of matrix metalloproteinase enzymes 2 and 9, and thereby promotes EMT, migration, invasion, and lung metastasis [192]. Interestingly, miR-29 is predicted to target the expression of AIB1, suggesting that the *p53/p73-miR-29-AIB1* pathway may inhibit breast cancer invasion and lung metastasis [Target scan]. Further, p63+/−, p73+/− and

E2F-1−/− mice have been shown to develop sarcoma—which is derived mainly from mesenchymal cell type—and metastatic tumors, suggesting that p63, p73 and E2F-1 could function as negative regulators of EMT and positive regulators of mesenchymal to epithelial transition (MET). In support of this notion, p73/p63/p53 has been hypothesized to increase the MET/EMT ratio by increasing the expression of tumor suppressor miRNAs, such as *miR-200, let-7, miR-34, miR-183, miR-203, miR-145, miR-141, miR-29, and miR-148* [53, 54]. Together, p73/p63/p53, by increasing the MET/EMT ratio through its target miRs, it could function as a negative regulator of metastasis (Fig. 6).

6 The p53/TA-p73/p63 ——| c-myc ——| miR-34 tumor suppressor pathway

The tumor suppressor miR-34 (1p36.22) has shown to be downregulated in cancers such as CLL, glioma, adenocarcinoma of the lung, and nasopharengial carcinoma [193]. A number of groups have shown that it is a direct transcriptional target of the tumor suppressor p53 (possibly, p73) [194, 195]. Interestingly, c-myc has been shown to suppress the expression of miR-34 [123], suggesting that reactivation of p53 in c-Myc over expressing human cancers may restore its expression. miR-34 appears to inhibit (or, target) the expression of—*Cyc D1, CDK6, Bcl2, SIRT1, Jagged1, Notch1/2/3, E2F3/1, steroid receptor coactivator-1 (SRC-1)*, ROCK-1*,-2*, mTORC1*, TMPRSS4*, Src*, TGFβ3*, TBX1*, FN1*, Hey-1*, DLL-1**—a number of key genes required for survival, cell cycle regulation, proliferation, invasion, and metastasis [196–198; Target scan; *-predicted]. Interestingly, E2F3, a key component in cell cycle progression, has been shown to repress the expression of the tumor suppressor p14ARF [197], suggesting that p53/p73-dependent upregulation of miR-34 may result in downregulation of E2F3 and upregulation of p14ARF (Fig. 6). Further, SRC-1, a co-activator of nuclear hormone (estrogen and progesterone) receptors, has been shown to increase the expression of c-myc through Ets-2 [199]. It also appears to induce the expression of TWIST (a negative regulator of E-cadherin) in conjunction with PEA3 and thereby promotes breast cancer progression and lung metastasis [200]. Interestingly, miR-34/130*, a direct (*-putative) transcriptional target of p53/p73* [113], appears to target the expression of SRC-1 [Target scan], suggesting that the *p53/p73-miR-34/130-SRC-1-ETS-2-c-myc-Twist1—E-cadherin* tumor suppressor pathway may inhibit EMT, breast cancer progression and lung metastasis. It has recently been shown that LEF1 is required for the invasion of lung adenocarcinomas to brain and bone [201]. Interestingly, miR-34 is predicted to inhibit the expression of LEF1 (Target scan), suggesting that p73/p53-dependent upregulation of miR-34 may downregulate the expression of

LEF1, and thereby inhibit the metastasis of lung adenocarcinomas to brain and bone.

7 The p53/TA-p73/p63 ⊣ c-myc ⊣ miR-15a/16-1 tumor suppressor pathway

The tumor suppressor miR-15a/16-1 has shown to be deleted/downregulated in B-cell CLL, non-small cell lung cancer, and prostate cancer [202, 203]. It appears to suppress the expression of cell cycle progression/proliferation/survival/metastasis/stem cell renewal promoting genes, such as *Bcl-2, Wnt-3a, Cyc D1, Cyc D2, Cyc D3, Cyc E1, CDK6, Mcl-1, MCM5, c-Myb, BMI-1, HMGA2* (*promotes neural stem cell renewal*), *c-Jun*, NFKB*, IKKβ*, VEGFA*, SMAD3*, mDIA1*, Raf-1*, TGFβR3*, Notch2*, DLL4*(Delta-like 4 Notch ligand), DLL1*, and Ets-1** [202–205; Target scan/Mami/Diana-*-predicted; Boominathan, unpublished] (Fig. 6). Interestingly, IKKβ, an NFKB activating kinase, has been shown to degrade ΔN-p63 [206], suggesting that the tumor suppressor miR-15a/16-1, by targeting its expression, it could control the expression of ΔN-p63. Considering that ΔN-p63 could function as a metastasis/tumor suppressor in a cell context-dependent manner, this supposition is of great significance. Further, miR-15a/16-1 has been shown to suppress the negative regulator of CDKN1A/INK4a/PTEN expression, BMI-1 (Fig. 5), suggesting that increased expression of miR-15a/16-1 may increase the expression of tumor suppressor CDKN1A/INK4a/PTEN [207]. Of interest, BMI-1 is a transcriptional target of c-myc (Fig. 5). Remarkably, BMI-1 has been shown to promote expansion of bronchiolalveolar stem cells, the putative initiators of the adenocarcinoma of the lung [208], suggesting that the tumor suppressor miR-15a/16-1, by suppressing the expression of BMI-1, it could hamper the expansion of bronchiolalveolar stem cells and thereby inhibit lung adenocarcinoma development. This is a significant finding considering TA-p73 and E2F-1 null mice are prone to lung adenocarcinoma. The fact that BMI-1 is transcriptional target of c-myc suggests that uncontrolled expression of c-myc may promote the expansion of bronchiolalveolar stem cells in TA-p73 null mice and thereby cause lung adenocarcinoma. Remarkably, knockdown of miR-15a/16-1 promotes survival, proliferation, and invasiveness of normal untransformed prostate cells, suggesting that it could also function as a tumor suppressor in prostate cancer [202]. Together, this data suggests a tumor suppressor pathway involving TA-*p73, p53, p63, c-myc, miR-15a, 16-1, BMI-1, INK4a, and PTEN* proteins/miRs.

Further, E2F-1/3 has recently been shown to bind to miR-15b/16-2 promoter and thereby increases its transcription [209]. Interestingly, E2F-1/3-dependent upregulation of miR-15b/16-2 inhibits S-phase progression by targeting multiple cell cycle regulators and E2F targets. Based on these interesting data, I hypothesized that miR-15/16-1 could be a transcriptional target of p53/p63/p73. Evidently, bioinformatics analysis of miR-15/16-1 cluster promoter (*miR-15a* {−1724 to −1743: (agg**catg**gtg)(gct**cttg**cct); −2598 to −2623: (ggc**cgag**gca)ggᶜgga(tca**cgag**gtc); −2654 to −2674: (atc**ctgg**gct)(ggg**catg**gtg); −4432 to −4463: ttg**catg**cta)(caa**catg**gat)g(aat**cttg**aaa)}; and *miR-16a*{(−1864 to −1884): (agg**catg**gtg)(gct**cttg**cct); −2737 to −2763: (ggc**cgag**gca)ggᶜgga(tca**cgag**gtc); −2794 to −2813: (atc**ctgg**gct)(ggg**catg**gtg); −4573 to −4594: (ttg**catg**cta)(caa**catg**gat)g(aat**cttg**aaa)}) revealed a number of p53REs, suggesting that it could be a putative transcriptional target of p53/TA-p73/p63. In support of this data, it has been shown that activation of p53 results in increased expression of miR-15a (5.2-fold), miR-15b (8.2-fold) and miR-16 (2.9-fold) [118], suggesting a possibility that they could be direct transcriptional targets of p53/TA-p73/p63. Taken together, these data suggest that the *E2F-1-p73/p53/p63-miR-145/let-7/miR-34;PTEN/FBXW7-c-myc-miR-15a/16-1/miR-15b/16-2 tumor suppressor network,* by suppressing the expression of genes that promote cell cycle progression, invasion, metastasis, survival, self-renewal, and CSCs proliferation, it could promote tumor suppression. In particular, the *E2F-1/2*-TA-p73*/p63*-let-7#/miR-15a/16-1#/PTEN#/INK4a#* tumor suppressor pathway (*lung cancer phenotype/#inhibits lung cancer) may play a critical role in the inhibition of adenocarcinoma of the lung.

8 The p53/TA-p73/p63 —— c-myc —— miR-26 tumor suppressor pathway

The tumor suppressor miR-26 has shown to be consistently suppressed by c-myc in a number of tumors [210], suggesting that it could play a role in myc-induced lymphomagenesis. It has recently been shown to suppress the expression of enhancer of zeste homologue 2 [EZH2], a histone methyl transferase and a component of polycomb repressive complex 2 [210] (Fig. 6). EZH2, by mediating methylation on histone H3 at lysine 27 (H3K27me3), it represses the transcription of a number of genes. It has shown to be over expressed in a number of human cancers, including human Burkitt lymphoma and rhabdomyosarcoma. It appears to promote hypermethylation; and increase pluripotency in stem cells. Remarkably, EZH2 appears to suppress the expression of key tumor suppressor genes, such as E-cadherin, AML-2/Runx-3, INK4A, INK4B, CDKN1C/p57Kip2, and PSP94 [188, 210–217]. This data suggests that c-Myc-mediated suppression of miR-26 may result in increased expression of EZH2 (H3K27me3 mark

on promoters) and decreased expression of its target genes (E-cadherin, AML-2, INK4A, INK4B, CDKN1C/p57Kip2, and PSP94). Further, it has been shown that systemic administration of miR-26a-adeno associated virus in a mouse model of hepatocellular carcinoma results in inhibition of tumor progression and induction of tumor specific apoptosis [218]. Interestingly, miR-26 is predicted to target the negative regulator of (a) p53, *HDM2*; (b) INK4a and ARF, *HMGA2*; and (c) p53/CDKN1B/C/p130, *Skp2* (Fig. 6) [http://www.targetscan.org/, http://diana.cslab.ece.ntua.gr/microT/, http://mami.med.harvard.edu/; Boominathan, unpublished]. This data suggests a possibility that miR-26, by downregulating the expression of HDM2, HMGA2, and Skp2, it could increase the expression of tumor suppressors p53, INK4a, ARF, p130, and CDKN1B/C. Given that correcting pathway-specific defects is essential for better management of cancer therapy, designing miR-26 mimics will be helpful.

Further, miR-26b has shown to be induced (5.8-fold) in response to p53 activation [118]. In support of this data, bioinformatics analysis of its promoter revealed a number of p53REs (Boominathan, unpublished), suggesting that it could be a transcriptional target of p53/TA-p63/p73. When this manuscript was under preparation, miR-101 has shown to inhibit the expression of EZH2 [219]. Interestingly, miR-101 (downregulated in transitional cell carcinoma) also appears to be a transcriptional target of p53, suggesting that p53 could inhibit the expression of EZH2 through both miR-29 and miR-101.

Further, miR-26b is predicted to suppress the expression of DNMT3b, Klf-4, HOXA9, HMGA2, Jagged-1, Hes-1 (over expression induces TCL; a negative regulator of the tumor suppressor PTEN; and a negative target of ΔNp63: ΔNp63 ⊣ Hes1 ⊣ PTEN), HIF-2α, AIB, and Prostasin [Target scan/mami]. Interestingly, HOXA9/HIF-2α has shown to be required for the survival of HSCs [220]. Remarkably, suppression of HOXA9 results in apoptosis of MLL-rearranged leukemias [220], suggesting that TA-p73 by increasing the expression of miR-26, it could hamper leukemia development. Loss of p53/TA-p73/p63-mediated c-myc suppression may result in decreased expression of miR-26 and increased expression of DNMT3b and EZH2. This in turn may result in epigenetic inactivation of tumor suppressor genes. Interestingly, it has recently been shown that systemic administration of miR-26 in a mouse model of hepatocellular carcinoma results in downregulation of Cyc D2 and Cyc E2 and inhibition of cancer cell proliferation and apoptosis [218]. Next, Klf-4 has shown to play a role in the generation of induced pluripotent stem cells from differentiated cells. Interestingly, it appears to suppress the expression of tumor suppressor p53 in a context-dependent manner [221]. This data suggest a possibility that miR-26, by

suppressing the expression of Klf-4 (Target scan), it could increase the expression of p53. Taken together, the *p53/ p73/p63-c-myc-miR-26-EZH2-INK4a/ARF/p130/ CDKN1B/C-DNMT3b/Klf-4/HOXA9/HMGA2/Jagged-1/ HIF-2α/AIB* tumor suppressor pathway may play a critical role in the inhibition of lymphoma, rhabdomyosarcoma, and hepatocellular carcinoma.

9 The p53/TA-p73/p63 ⊣ c-myc ⊣ miR-30b/c/d tumor suppressor pathway

Another miRNA that has shown to be suppressed in response to high levels of c-myc is miR-30b/c/d [123]. Analysis of miR-30's predicted targets suggests that it may suppress: (a) Lin-28, the negative regulator of the tumor suppressor miRNA, let-7 processing; (b) DNMT3a; (c) Skp2, which targets CDKN1B/C/p130 for degradation; (d) AIB1; (e) DLL-4, Jagged-2 and Notch-1; (f) PTP4A1; (g) SMAD2; (h) SIRT1, and (i) WWP1 (Target scan; Fig. 6).

It has recently been shown that WWP1, a WW domain containing protein, binds to TA-p63 and ubiquitinates it. By ubiquitinating TA-p63, WWP1 targets TA-p63 for degradation through proteasomes [222]. This data suggests that miR-30, by downregulating the expression of WWP1, it could increase the expression of the tumor suppressor TA-p63 in a cell context-dependent manner (Fig. 6; Boominathan, unpublished).

In addition, miR-30 appears to target the positive regulators of EMT/migration, such as Snail1/Slug, PTP4A1, and Vimentin-1 (mesenchymal marker) [Target scan]. This data suggests a possibility that miR-30, by negatively regulating the expression of Snail1/Slug, it could increase the expression of E-cadherin, and thereby inhibit EMT transition and metastasis. As discussed, Snail1 negatively regulates the expression of ΔN-p63, and thereby promotes the invasive property of human SCC. This data suggests a possibility that p63/p73/p53-induced miR-30 expression may result in downregulation of Snail1 and upregulation of ΔN-p63/E-cadherin and inhibition of invasion and metastasis. Remarkably, it has recently been shown that miR-30 reduces self-renewal of breast tumor-initiating cells (BT-ICs) by suppressing the expression of Ubc9 and Integrin β-3 [223]. In addition, over expression of miR-30 in BT-ICs xenografts reduces tumorigenesis and lung metastasis in immunodeficient mice [223]. Further, it has recently been shown that expression of miR-30 in thyroid carcinoma-derived cells promotes mesenchymal to epithelial transition by reducing the expression of TGFβRI. This in turn reduces the invasive potential of thyroid carcinoma-derived cells [224]. Together, these data suggest that expression of miR-30 may inhibit EMT, self-renewal of tumor-initiating cells, invasion, and metastasis. These

promising findings present us with a therapeutic opportunity. That is, by reintroducing miR-30b/c/d into cancer cells, one could suppress the expression of WWP1, Lin-28, Snail1, and DNMT3a, and thereby increase the expression of the tumor suppressors p63, let-7, TAp73, PTEN, CDKN1C, and E-cadherin (Fig. 6; Boominathan, unpublished). Therefore, this data suggests a possibility that miR-30 mimics will be useful in cancer therapy. Remarkably, activation of p53 has been shown to increase the expression of miR-30c [225] and miR-30a-3p (1.6-fold) [118]. In support of this data, bioinformatics analysis of miR-30 cluster promoters revealed a number of p53REs, suggesting a possibility that they could be transcriptional targets of p53/p63/p73 [Boominathan, unpublished]. Taken together, the *p53/p73-c-myc-miR-30-p63/let-7/CDKN1B/C/p130/E-cadherin* tumor suppressor pathway may play a critical role in the inhibition of EMT, invasion, metastasis, and breast cancer stem cells.

10 The p53/TA-p73/p63 ——————| c-myc ——————| miR-23 tumor suppressor pathway

c-Myc has recently been shown to suppress the expression of miR-23 [173]. Interestingly, miR-23 has been predicted to suppress the expression of HIF-2α* [Target scan; Boominathan, submitted; *predicted]. HIF-2α is over expressed in non-small lung carcinoma, renal carcinoma, and glioblastoma. Interestingly, HIF-2α co-operates with K-ras mutant to promote more invasive lung cancer [226]. This cancer is characterized by increased EMT, angiogenesis, and mobilization of endothelial progenitor cells [226]. Further, HIF-2α has shown to be predominantly expressed in glioma stem cells compared with non-stem tumor cells and normal neural progenitors [227]. In glioma stem cells, it appears to co-localize with the stem cell marker CD133 [227]. Interestingly, suppression of HIF-2α in glioma stem cells inhibits self-renewal, proliferation, survival, and tumor initiation potential [227]. These data suggest that p63/p73/p53-dependent upregulation of miR-23 may result in downregulation of HIF-2α and its target genes, such as Oct4, c-myc, Lin-28*, Esrrb*, klf4*, Sox-2/4*, and telomerase* [228–230; *-putative; Boominathan, submitted]. In addition, downregulation of HIF-2α may result in decreased expression of VEGFA, lysil oxidase, and Twist-1 [229, 230]. Interestingly, HIF-dependent expression of Twist-1 and miR-10b [that increases the expression of metastatic promoting gene such as Rho-c by downregulating the expression of HB10D] has been shown to promote EMT and metastasis (Fig. 4). Furthermore, miR-23 has been shown to target the expression of (a) ZEB1*, TGFβR-2* and -3* mRNAs, (negative regulators of the metastasis suppressor E-cadherin); (b) Skp2*, which appears to promote the c-Myc-Miz-1-p300-RhoA metastasis cascade [134] (Fig. 4); (c) proteins that play a role in invasion and metastasis, such as Urokinase-type plasminogen activator and c-Met [46]; (d) SIRT1*; and (e) the metastasis promoter SRC-1*, which appears to increase the Ets-2-c-myc-Twist metastasis cascade [199, 200; *predicted].

Remarkably, activation of p53 has been shown to increase the expression of miR-23a (3.5-fold) and miR-23-b (1.7-fold) [118]. In support of this data, bioinformatics analysis of miR-23a/b promoter revealed a number of p53REs, suggesting that it could be a direct transcriptional target of p53/TAp73/p63. Thus, p53/TA-p73/p63, by activating the *let-7/miR-145-c-myc-miR-23-HIF-2α/ZEB1/CDH1/INK4b/Skp2* tumor suppressor pathway, it could inhibit CSCs proliferation, EMT, and metastasis (Fig. 4).

11 The p53/TA-p73/p63 ——————| c-myc ——————| miR-146a tumor suppressor pathway

Yet another miRNA that has been shown to be suppressed in response to high levels of c-myc is miR-146 [123]. Interestingly, bioinformatics analysis of its promoter revealed a number of p53REs, suggesting that it could be a direct transcriptional target of p53 (Boominathan, unpublished). Downregulation of miR-146 has been shown to play a critical role in the progression of papillary thyroid carcinoma [231]. Furthermore, polymorphisms in miR-146 gene results in decreased mature miR-146 transcript in thyroid cancer [232]. Loss of miR-146a expression has also been shown in prostate cancer; and reintroduction of miR-146a into prostate cancer cells results in reduced proliferation, invasion, and metastasis [233]. Interestingly, breast cancer metastasis suppressor-1, a suppressor of NFKB and miR-10b expression, has recently been shown to increase the expression of miR-146 [234]; and reintroduction of miR-146 into breast cancer cells results in downregulation of EGFR expression and inhibition of invasion, migration, and metastasis [234] (Fig. 6). Further, c-Myc's transcriptional target, miR-17–92 cluster is predicted to suppress the expression of Breast cancer metastasis suppressor-1 [Target scan], suggesting that it could inhibit the upregulation of miR-146 (Fig. 5). Interestingly, miR-146 is predicted to target β-catenin (Target scan), which has been shown to promote the generation of stem cells in CML [133]. Together, these data suggest that p53/TAp73/p63, by suppressing the expression of c-Myc, it could increase the expression of breast cancer metastasis suppressor-1, and thereby increase the expression of miR-146 to prevent invasion, migration, metastasis, and CSCs proliferation.

12 The p53/TA-p73/p63 ➝ miR-192, 215, 145 —⊣ ZEB2/SIP1 —⊣ E-cadherin; The p53/TA-p73/p63 ➝ miR-145/34/let-7 —⊣ c-myc ➝ miR-9-3 —⊣ E-cadherin; The p53/TA-p73/p63 ➝ miR-145/34/let-7 —⊣ c-myc —⊣ miR-221/222 —⊣ TIMP3/PTEN/CDKN1b, c tumor suppressor pathways

As previously discussed, miR-145, and miR-192/215 are transcriptional targets of the tumor suppressor p53/TA-p73/p63. Bioinformatics analysis of miR-145 and miR-192/215 targets suggests that they may suppress the expression of ZEB2/SIP1 [SMAD1 interacting protein 1] [Target scan]. Together, these data suggest that p53, p63, and p73, by increasing the expression of miRs-192, -215, and -145, they could suppress the expression of ZEB2 (Fig. 4) [53, 54]. Remarkably, ZEB2 also appears to be a common target of a number of other p53-induced miRs, such as miR-30a-e, miR-200b/c, miR-183, miR-92a/b, miR-132, suggesting a conserved mechanism mediating the p53/p63/p73-dependent inhibition of EMT, invasion, and metastasis [53]. ZEB2 has been shown to function as a repressor of the tumor suppressor E-cadherin, suggesting that p53, TA-p73, and TA-p63, by suppressing the expression of ZEB2, they could increase the expression of E-cadherin (Fig. 4) [54]. This in turn could inhibit EMT, invasion, and metastasis [235]. Of interest, activation of EMT has been shown to promote generation of cells with stem cell properties (e.g., expression of stem cell markers) [236], suggesting that p53-miR-dependent upregulation of E-cadherin (or, inhibition of EMT) could inhibit the generation of CSCs.

Further, it has recently been shown that miR-9-a-3 is a transcriptional target of c-Myc/MYCN [237]. Interestingly, increased expression of miR-9-a-3 has been shown to suppress the expression of E-cadherin and its downstream targets, such as β-catenin and VEGF [237, 238]. This data suggests that activation of the p53/TA-p73/p63-miR-145/34/let-7 pathway may downregulate both c-myc and its downstream target miRNA, miR-9-a-3, and thereby upregulate the expression of E-cadherin (Fig. 5). This in turn will result in downregulation of β-catenin and VEGF and inhibition of invasion and metastasis. Interestingly, N-myc downstream-regulated gene 1, a transcriptional target of p53 and a metastasis suppressor, appears to be targeted by miR-9 (Target scan), suggesting that p73/p63/p53, by decreasing the expression of c-myc/miR-9-a-3, it could increase its expression, and thereby inhibit metastasis [239].

A recent study suggests that c-myc increases the expression of miR-221, and miR-222 [240]. Another study suggests that these miRNAs are transactivated by c-met/c-Jun [241]. Furthermore, increased expression of miR-221/miR-222 suppresses the expression of the tumor/metastasis suppressor proteins such as PTEN and TIMP3 (Fig. 5) [241]. Interestingly, increased expression of miR-221/222

has been inversely correlated with the expression of TIMP3 and PTEN in human non-small cell lung carcinoma and hepatocellular carcinoma. Yet another important study suggests that miR-221/222 suppresses the expression of CDK inhibitors, such as CDKN1B and CDKN1C [242] (Fig. 5). These data together suggest that p53-miRs (miR-145, miR-34, and miR-let-7)-dependent suppression of c-myc/c-met/c-Jun expression may result in decreased expression of miR-221/222. This in turn will result in upregulation of PTEN, CDKN1B, CDKN1C, and TIMP3 expression, and inhibition of tumorigenesis, migration, and invasion. Taken together, the data discussed in this article strongly suggest that p53, TA-p73, and p63 could function as negative regulators of the EMT, migration, invasion, metastasis, and CSCs proliferation.

13 Conclusion

The match between c-myc-suppressed tumor suppressor miRNAs [172] and p53-induced miRNAs [118] suggests a link between p53-activated and c-myc-suppressed miRNAs-dependent tumor suppressor pathways. p53/TA-p73/p63, by suppressing the expression of c-myc through *TRIM32/PTEN/FBXW7/miR-145/34/let-7*, it could upregulate the expression of tumor suppressor miRNAs, such as *miR-15/16a, miR-29, miR-34, miR-26, let-7a/d/g, miR-30b/c/d/e, miR-146a, miR-150 and miR-22*, and a number of tumor suppressor genes (Figs.5 and 6). Evidently, inactivation of c-myc has been shown to induce senescence by inducing INK4a and INK4B expression [243, 244]. This could perhaps be due to the downregulation of the c-myc's target genes BMI-1 and HMGA2 (an indirect target) (Fig. 3). It appears that p53/TA-p73/p63-mediated repression of c-myc [and its repressed miRNA targets] is disadvantageous for AML, glioblastoma, acute lymphoblastic leukemia, adenocarcinoma of the lung, and B-cell lymphoma [172]. In support of this data, it has recently been shown that: (a) knockdown of p73 promotes dissemination of c-myc-induced B-cell lymphomas [245]; (b) inactivation of both p53 and its target gene PTEN results in activation of c-myc in glioblastoma. This in turn results in increased self-renewal of neural stem cells/tumor-initiating cells [246]; and (c) deletion of PTEN in HSCs increases the expression of β-catenin and c-myc. This in turn results in increased number of leukemic stem cells, which aid the progression of acute T-cell lymphoblastic leukemia [247]. The fact that deletion of PTEN in T-cells/hematopoietic stem cells/bronchioalveolar epithelium increases the expression of c-myc suggests that they share a double negative feedback loop (c-myc-miR-17–92-PTEN; PTEN-c-myc) [248, 249]. Together, these data suggest that tumors that harbor mutation in p53/PTEN(the second most frequently mutated gene next to the p53 tumor suppressor)/FBXW7 gene will have

increased levels of c-myc, which in turn will activate oncogenic miRNAs and thereby suppress a number of tumor suppressor miRNAs/genes (Figs. 4, 5, and 6).

It has recently been shown that c-myc promotes k-ras/c-Raf-driven metastasis in a mouse model of non-small cell lung carcinoma, and inactivation of both c-myc and k-ras inhibits tumorigenesis of lung cancer/lymphomas. Remarkably, both c-myc and k-ras expression are suppressed by the tumor suppressor miRNA, let-7, suggesting that reintroduction of let-7 or its mimics may be helpful for patients suffering from lung adenocarcinoma and lymphoma.

In support of the data discussed in this article, c-myc-suppressed miRNAs—such as let-7, miR-34a-c, miR-15/16, and miR-29—are downregulated in lung cancer, while c-myc-activated miRNAs—such as miR-17–92 and miR-221/222—are upregulated [250], suggesting that the c-myc-orchestrated activation/suppression of the miRNAs may play an important role in tumor suppression.

Further, the p63-AML1/Runx-1-ARF tumor suppressor pathway may suppress the transcriptional activity of c-myc, as ARF has been shown to suppress its transcriptional activity [251]. Likewise, the E2F-1-p73-JunB-INK4a/ARF tumor suppressor pathway may suppress the transcriptional activity of c-myc, as ARF is a transcriptional target of E2F-1. Remarkably, p73 loss of heterozygosity has been observed in 60% of human non-small cell lung carcinomas that harbor mutation either in p14ARF or p53 gene, suggesting the importance of the E2F-1-TA-p73-ARF pathway in inhibiting the development of non-small cell lung carcinomas [1, 252]. Furthermore, JunB, a putative target of p73/p63, has been shown to increase the expression of the lung cancer suppressor DMTF (deleted in 40% of human non-small cell lung cancer) [253]. Bioinformatics analysis of its promoter revealed a number of p53/p63-REs, suggesting that it could be a transcriptional target of p73/p53/p63. Interestingly, increased expression of DMTF has been shown to increase the expression of ARF [254, 255], suggesting that the p73/p63-JunB/DMTF-ARF tumor-suppressor pathway may suppress the expression of c-myc. Considering TAp73, p73, p63, E2F1 and DMTF heterozygous/null mice are prone to lung adenocarcinoma suggests that they may co-operate with each other in tumor suppression. Together, these findings suggest that TA-p73 and p63: (a) may suppress the expression of c-myc, and thereby increase the expression of c-myc-repressed tumor suppressor miRNAs/genes; and (b) are no longer the specter of the tumor/metastasis suppressors, but they are indeed tumor/metastasis suppressors.

In addition, p53/TAp73/p63 could increase the expression of a number of tumor suppressor miRNAs directly. Therefore, the data discussed in this article posit that reintroduction of p53/TA-p63/p73-dependent miRNAs, such as *miR-145, miR-23, let-7, miR-15/16, miR-26, miR-29, miR-30, and miR-34*, in *human cancers over expressing*

c-myc will upregulate the tumor suppressor miRNAs/genes and thereby inhibit tumor progression, invasion, metastasis, and CSCs proliferation. Considering "pathway-specific therapy" will be the mode of treatment in the future for better cancer management, the tumor suppressor pathways described in this article may aid cancer therapy.

Malone and Hannon [256] have recently suggested that small RNAs may be considered as guardians of the genome. Remarkably, it appears that most of the known miRNA processing components, including Drosha, DGCR8, Dicer, Ago-1(miRNA)/-3(piRNA)/-4(rasiRNA)(1p34-35), TARBP2, and p68/p72, are regulated by p53/p73/p63 and its target miRNAs [113]. In particular, p53-miRs appear to target the miRNA processing enzyme Dicer in a context-dependent manner [113]; and p63/p73 may increase the transcription of dicer and thereby inhibit metastasis [113]. Interestingly, deletion of dicer has been shown to elicit a DNA damage response, increase the tumor suppressor p53-ARF pathway, promote senescence, and inhibit stem cell renewal/proliferation [113]. This data suggests that p53/p63/p73, by regulating dicer in a cell context-dependent manner, could inhibit tumorigenesis, metastasis, and stem cell (possibly CSCs) proliferation/self-renewal [113]. In addition, genome sequence analysis suggests that nearly half of the 326 miRNA promoters contain p53-REs [257]. Therefore, p53, p63, and p73, by regulating both the miRNAs expression and their processing components, they could function as regulators of the *miRNA/siRNA/piRNA* (silences transposons in the germ line)/*rasiRNA* (suppresses DNA damage response in the germ line) biogenesis [258, 259]. Together, the data discussed in this article suggests for the first time that the guardian of the genome p53 and its homologues p73 and p63 are in control of the production of small RNAs. In conclusion, "the guardians of the genome" p53, TA-p73, and TA-p63 are not only in control of the expression of a number of protein-coding tumor suppressor genes, but also non-coding tumor suppressor small RNAs [260].

References

1. Boominathan, L. (2007). Some facts and thoughts: p73 as a tumor suppressor gene in the network of tumor suppressors. *Molecular Cancer, 6*, 27.
2. Chen, H. Z., Tsai, S. Y., & Leone, G. (2009). Emerging roles of E2Fs in cancer: an exit from cell cycle control. *Nat Rev Cancer, 9*(11), 785–97.

3. Puig, P., Capodieci, P., Drobnjak, M., Verbel, D., Prives, C., Cordon-Cardo, C., et al. (2003). p73 expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. *Clinical Cancer Research, 9*(15), 5642–5651.

4. Urist, M. J., Di Como, C. J., Lu, M. L., Charytonowicz, E., Verbel, D., Crum, C. P., et al. (2002). Loss of p63 expression is associated with tumor progression in bladder cancer. *The American Journal of Pathology, 161*(4), 1199–1206.

5. Park, B. J., Lee, S. J., Kim, J. I., Lee, S. J., Lee, C. H., Chang, S. G., et al. (2000). Frequent alteration of p63 expression in human primary bladder carcinomas. *Cancer Research, 60*(13), 3370–3374.

6. Oya, M., & Schulz, W. A. (2000). Decreased expression of p57 (KIP2)mRNA in human bladder cancer. *British Journal of Cancer, 83*(5), 626–631.

7. Kunze, E., Wendt, M., & Schlott, T. (2006). Promoter hyper-methylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas. *International Journal of Molecular Medicine, 18*(4), 547–557.

8. Moreira, J. M., Gromov, P., & Celis, J. E. (2004). Expression of the tumor suppressor protein 14-3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. *Molecular & Cellular Proteomics, 3*(4), 410–419.

9. Le Frère-Belda, M. A., Cappellen, D., Daher, A., Gil-Diez-de-Medina, S., Besse, F., Abbou, C. C., et al. (2001). p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours. *British Journal of Cancer, 85*(10), 1515–1521.

10. Pymar, L. S., Platt, F. M., Askham, J. M., Morrison, E. E., & Knowles, M. A. (2008). Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. *Human Molecular Genetics, 17*(13), 2006–2017.

11. Vecchione, A., Ishii, H., Baldassarre, G., Bassi, P., Trapasso, F., Alder, H., et al. (2002). FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. *The American Journal of Pathology, 160*(4), 1345–1352.

12. Tsuruta, H., Kishimoto, H., Sasaki, T., Horie, Y., Natsui, M., Shibata, Y., et al. (2006). Hyperplasia and carcinomas in PTEN-deficient mice and reduced PTEN protein in human bladder cancer patients. *Cancer Research, 66*(17), 8389–8396.

13. Kim, E. J., Kim, Y. J., Jeong, P., Ha, Y. S., Bae, S. C., & Kim, W. J. (2008). Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. *Urology, 180*(3), 1141–1145.

14. Ostenfeld, M. S., Bramsen, J. B., Lamy, P., Villadsen, S. B., Fristrup, N., Sørensen, K. D., et al. (2010). miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. *Oncogene, 29*(7), 1073–1084.

15. Wiklund, E.D., Bramsen, J.B., Hulf, T., Dyrskjøt, L., Ramana-than, R., Hansen, T.B., et al. (2010). Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. *Int J Cancer* (in press)

16. Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., et al. (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. *Cell, 131*(6), 1109–1123.

17. Mo, L., Zheng, X., Huang, H. Y., Shapiro, E., Lepor, H., Cordon-Cardo, C., et al. (2007). Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. *The Journal of Clinical Investigation, 117*(2), 314–325.

18. Knowles, M. A., Platt, F. M., Ross, R. L., & Hurst, C. D. (2009). Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. *Cancer and Metastasis Reviews, 28*(3–4), 305–316. Review.

19. Tomasini, R., Tsuchihara, K., Wilhelm, M., Fujitani, M., Rufini, A., Cheung, C. C., et al. (2008). TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. *Genes & Development, 22*(19), 2677–2691.

20. He, L., Fan, C., Ning, X., Feng, X., Liu, Y., Chen, B., et al. (2008). Interaction of p14ARF with Brca1 in cancer cell lines and primary breast cancer. *Cell Biology International, 32*(10), 1302–1309.

21. Zhu, J. W., Field, S. J., Gore, L., Thompson, M., Yang, H., Fujiwara, Y., et al. (2001). E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. *Molecular and Cellular Biology, 2001*(24), 8547–8564.

22. Opavsky, R., Tsai, S. Y., Guimond, M., Arora, A., Opavska, J., Becknell, B., et al. (2007). Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. *Proceedings of the National Academy of Sciences of the United States of America, 104*(39), 15400–15405.

23. Friedman, L. S., Thistlethwaite, F. C., Patel, K. J., Yu, V. P., Lee, H., Venkitaraman, A. R., et al. (1998). Thymic lymphomas in mice with a truncating mutation in Brca2. *Cancer Research, 58*(7), 1338–1343.

24. Szremska, A. P., Kenner, L., Weisz, E., Ott, R. G., Passegué, E., Artwohl, M., et al. (2003). JunB inhibits proliferation and transformation in B-lymphoid cells. *Blood, 102*(12), 4159–4165.

25. Passegué, E., & Wagner, E. F. (2000). JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. *The EMBO Journal, 19*(12), 2969–2979.

26. Passegué, E., Jochum, W., Schorpp-Kistner, M., Möhle-Stein-lein, U., & Wagner, E. F. (2001). Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking JunB expression in the myeloid lineage. *Cell, 104*(1), 21–32.

27. Passegué, E., Wagner, E. F., & Weissman, I. L. (2004). JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. *Cell, 119*(3), 431–443.

28. Corn, P. G., Kuerbitz, S. J., van Noesel, M. M., Esteller, M., Compitello, N., Baylin, S. B., et al. (1999). Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. *Cancer Research, 59*(14), 3352–3356.

29. Yamaguchi, H., Inokuchi, K., Sakuma, Y., & Dan, K. (2001). Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. *Leukemia, 11*, 1729–1734.

30. Marreiros, A., Dudgeon, K., Dao, V., Grimm, M. O., Czolij, R., Crossley, M., et al. (2005). KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells. *Oncogene, 24*(4), 637–649.

31. Koster, M. I., Kim, S., Huang, J., Williams, T., & Roop, D. R. (2006). TAp63alpha induces AP-2gamma as an early event in epidermal morphogenesis. *Developmental Biology, 289*(1), 253–261.

32. Li, H., Watts, G. S., Oshiro, M. M., Futscher, B. W., & Domann, F. E. (2006). AP-2alpha and AP-2gamma are transcriptional targets of p53 in human breast carcinoma cells. *Oncogene, 25*(39), 5405–5415.

33. Mitchell, D. C., Abdelrahim, M., Weng, J., Stafford, L. J., Safe, S., Bar-Eli, M., et al. (2006). Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1. *The Journal of Biological Chemistry, 281*(1), 51–58.

34. Sanchez-Carbayo, M., Capodieci, P., & Cordon-Cardo, C. (2003). Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progres-

sion and clinical outcome. *The American Journal of Pathology, 162*(2), 609–617.

35. Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., et al. (2006). Augmentation of tumor angiogenesis by a Myc-activated miRNA cluster. *Nature Genetics, 38*(9), 1060–1065.

36. Wang, S. P., Wang, W. L., Chang, Y. L., Wu, C. T., Chao, Y. C., Kao, S. H., et al. (2009). p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. *Nature Cell Biology, 6*, 694–704.

37. Lim, S. O., Kim, H., & Jung, G. (2010). p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma. *FEBS Letters, 584*(11), 2231–2236.

38. Kudo-Saito, C., Shirako, H., Takeuchi, T., & Kawakami, Y. (2009). Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. *Cancer Cell, 15*(3), 195–206.

39. Beach, S., Tang, H., Park, S., Dhillon, A. S., Keller, E. T., Kolch, W., et al. (2008). Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. *Oncogene, 27*(15), 2243–2248.

40. Jin, H., Yu, Y., Zhang, T., Zhou, X., Zhou, J., Jia, L., et al. (2010). Snail is critical for tumor growth and metastasis of ovarian carcinoma. *International Journal of Cancer, 126*(9), 2102–2111.

41. Dangi-Garimella, S., Yun, J., Eves, E. M., Newman, M., Erkeland, S. J., Hammond, S. M., et al. (2009). Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. *The EMBO Journal, 28*(4), 347–358.

42. Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., et al. (2000). Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. *Cell, 103*(2), 321–330.

43. Ozaki, T., Okoshi, R., Sang, M., Kubo, N., & Nakagawara, A. (2009). Acetylation status of E2F-1 has an important role in the regulation of E2F-1-mediated transactivation of tumor suppressor p73. *Biochemical and Biophysical Research Communications, 386*(1), 207–211.

44. Sayan, B. S., Sayan, A. E., Yang, A. L., Aqeilan, R. I., Candi, E., Cohen, G. M., et al. (2007). Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. *Proceedings of the National Academy of Sciences of the United States of America, 104*(26), 10871–10876.

45. Li, N., Fu, H., Tie, Y., Hu, Z., Kong, W., Wu, Y., et al. (2009). miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. *Cancer Letters, 275*(1), 44–53.

46. Salvi, A., Sabelli, C., Moncini, S., Venturin, M., Arici, B., Riva, P., et al. (2009). MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. *The FEBS Journal, 276*(11), 2966–2982.

47. Yamakuchi, M., Lotterman, C. D., Bao, C., Hruban, R. H., Karim, B., Mendell, J. T., et al. (2010). p53- induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. *Proceedings of the National Academy of Sciences of the United States of America, 107*(14), 6334–6339.

48. Sachdeva, M., & Mo, Y. Y. (2010). MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. *Cancer Research, 70*(1), 378–387.

49. Chen, X., Gong, J., Zeng, H., Chen, N., Huang, R., et al. (2010). MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. *Cancer Research, 70*(7), 2728–2738.

50. Chiyomaru, T., Enokida, H., Tatarano, S., Kawahara, K., Uchida, Y., Nishiyama, K., et al. (2010). miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. *British Journal of Cancer, 102*(5), 883–891.

51. Kano, M., Seki, N., Kikkawa, N., Fujimura, L., Hoshino, I., Akutsu, Y., Chiyomaru, T., Enokida, H., Nakagawa, M., Matsubara, H. (2010). miR-145, miR-133a and miR-133b: Tumor suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. *Int J Cancer* (in press)

52. Barbieri, C. E., Tang, L. J., Brown, K. A., & Pietenpol, J. A. (2006). Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. *Cancer Research, 66*(15), 7589–7597.

53. Boominathan, L. (2010). The Tumor suppressors p53, p63, and p73 inhibit migrating cancer stem cells by increasing the expression of stem cell suppressing miRNAs *Nature Precedings*, http://hdl.handle.net/10101/npre.2010.4385.1.

54. Boominathan, L. (2009). p63, p73, & p53 are negative regulators of epithelial to mesenchymal transition (EMT), invasion & metastasis. *Nature Precedings* http://dx.doi.org/10.1038/npre.2009.4109.1.

55. Leong, K. G., Niessen, K., Kulic, I., Raouf, A., Eaves, C., Pollet, I., et al. (2007). Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. *The Journal of Experimental Medicine, 204*(12), 2935–2948.

56. Hooper, C., Tavassoli, M., Chapple, J. P., Uwanogho, D., Goodyear, R., Melino, G., et al. (2006). TAp73 isoforms antagonize Notch signalling in SH-SY5Y neuroblastomas and in primary neurones. *Journal of Neurochemistry, 99*(3), 989–999.

57. Chu, W. K., Dai, P. M., Li, H. L., & Chen, J. K. (2008). Transcriptional activity of the DeltaNp63 promoter is regulated by STAT3. *The Journal of Biological Chemistry, 283*(12), 7328–7337.

58. Nishi, H., Senoo, M., Nishi, K. H., Murphy, B., Rikiyama, T., Matsumura, Y., et al. (2001). p53 Homologue p63 represses epidermal growth factor receptor expression. *The Journal of Biological Chemistry, 276*(45), 41717–41724.

59. Lo, H. W., Hsu, S. C., Xia, W., Cao, X., Shih, J. Y., Wei, Y., et al. (2007). Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial–mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. *Cancer Research, 67*(19), 9066–9076.

60. Cho, M. S., Chan, I. L., & Flores, E. R. (2010). DeltaNp63 transcriptionally regulates brachyury, a gene with diverse roles in limb development, tumorigenesis and metastasis. *Cell Cycle, 9*(12).

61. Fernando, R. I., Litzinger, M., Trono, P., Hamilton, D. H., Schlom, J., & Palena, C. (2010). The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. *The Journal of Clinical Investigation, 120*(2), 533–544.

62. Senoo, M., Matsumura, Y., & Habu, S. (2002). TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. *Oncogene, 21*(16), 2455–2465.

63. Yang, A. D., Camp, E. R., Fan, F., Shen, L., Gray, M. J., Liu, W., et al. (2006). Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. *Cancer Research, 66*(1), 46–51.

64. Mak, P., Leav, I., Pursell, B., Bae, D., Yang, X., Taglienti, C. A., et al. (2010). ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. *Cancer Cell, 17*(4), 319–332.

65. Yang, M. H., Wu, M. Z., Chiou, S. H., Chen, P. M., Chang, S. Y., Liu, C. J., et al. (2008). Direct regulation of TWIST by HIF-1alpha promotes metastasis. *Nature Cell Biology, 10*(3), 295–305.

66. Ansieau, S., Bastid, J., Doreau, A., Morel, A. P., Bouchet, B. P., Thomas, C., et al. (2008). Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. *Cancer Cell, 14*(1), 79–89.

67. Zhou, B. P., Deng, J., Xia, W., Xu, J., Li, Y. M., Gunduz, M., et al. (2004). Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial–mesenchymal transition. *Nature Cell Biology, 6*(10), 931–940.

68. Fukushima, H., Koga, F., Kawakami, S., Fujii, Y., Yoshida, S., Ratovitski, E., et al. (2009). Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. *Cancer Research, 69*(24), 9263–9270.

69. Shin, S., Dimitri, C. A., Yoon, S. O., Dowdle, W., & Blenis, J. (2010). ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. *Molecular Cell, 38*(1), 114–127.

70. Higashikawa, K., Yoneda, S., Tobiume, K., Saitoh, M., Taki, M., et al. (2009). DeltaNp63alpha-dependent expression of Id-3 distinctively suppresses the invasiveness of human squamous cell carcinoma. *International Journal of Cancer, 124*(12), 2837–2844.

71. Kommagani, R., Leonard, M. K., Lewis, S., Romano, R. A., Sinha, S., & Kadakia, M. P. (2009). Regulation of VDR by deltaNp63alpha is associated with inhibition of cell invasion. *Journal of Cell Science, 122*(Pt 16), 2828–2835.

72. Kommagani, R., Payal, V., & Kadakia, M. P. (2007). Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. *The Journal of Biological Chemistry, 282*(41), 29847–29854.

73. Pálmer, H. G., González-Sancho, J. M., Espada, J., Berciano, M. T., Puig, I., Baulida, J., et al. (2001). Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. *The Journal of Cell Biology, 154*(2), 369–387.

74. Pálmer, H. G., Larriba, M. J., García, J. M., Ordóñez-Morán, P., Peña, C., Peiró, S., et al. (2004). The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. *Natural Medicines, 10*(9), 917–919.

75. Peña, C., García, J. M., Silva, J., García, V., Rodríguez, R., Alonso, I., et al. (2005). E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations. *Human Molecular Genetics, 14*(22), 3361–3370.

76. Higashikawa, K., Yoneda, S., Tobiume, K., Taki, M., & Shigeishi, H. (2007). Snail-induced down-regulation of DeltaNp63alpha acquires invasive phenotype of human squamous cell carcinoma. *Cancer Research, 67*(19), 9207–9213.

77. Aberdam, D., Gambaro, K., Rostagno, P., Aberdam, E., de la Forest Divonne, S., & Rouleau, M. (2007). Key role of p63 in BMP-4-induced epidermal commitment of embryonic stem cells. *Cell Cycle, 6*(3), 291–294.

78. Chikh, A., Sayan, E., Thibaut, S., Lena, A. M., DiGiorgi, S., Bernard, B. A., et al. (2007). Expression of GATA-3 in epidermis and hair follicle: relationship to p63. *Biochemical and Biophysical Research Communications, 361*(1), 1–6.

79. Yan, W., Cao, Q. J., Arenas, R. B., Bentley, B., & Shao, R. (2010). GATA3 inhibits breast cancer metastasis through the reversal of epithelial–mesenchymal transition. *The Journal of Biological Chemistry, 285*(18), 14042–14051.

80. Kouros-Mehr, H., Bechis, S. K., Slorach, E. M., Littlepage, L. E., Egeblad, M., Ewald, A. J., et al. (2008). GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. *Cancer Cell, 13*(2), 141–152.

81. Dydensborg, A. B., Rose, A. A., Wilson, B. J., Grote, D., Paquet, M., Giguère, V., et al. (2009). GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. *Oncogene, 28*(29), 2634–2642.

82. Candi, E., Terrinoni, A., Rufini, A., Chikh, A., Lena, A. M., Suzuki, Y., et al. (2006). p63 is upstream of IKK alpha in epidermal development. *Journal of Cell Science, 119*(Pt 22), 4617–4622.

83. Descargues, P., Sil, A. K., & Karin, M. (2008). IKKalpha, a critical regulator of epidermal differentiation and a suppressor of skin cancer. *The EMBO Journal, 27*(20), 2639–2647.

84. Marinari, B., Ballaro, C., Koster, M. I., Giustizieri, M. L., Moretti, F., Crosti, F., et al. (2009). IKKalpha is a p63 transcriptional target involved in the pathogenesis of ectodermal dysplasias. *The Journal of Investigative Dermatology, 129*(1), 60–69.

85. Koster, M. I., Dai, D., Marinari, B., Sano, Y., Costanzo, A., Karin, M., et al. (2007). p63 induces key target genes required for epidermal morphogenesis. *Proceedings of the National Academy of Sciences of the United States of America, 104*(9), 3255–3260.

86. Beretta, C., Chiarelli, A., Testoni, B., Mantovani, R., & Guerrini, L. (2005). Regulation of the cyclin-dependent kinase inhibitor p57Kip2 expression by p63. *Cell Cycle, 11*, 1625–1631.

87. Carroll, D. K., Carroll, J. S., Leong, C. O., Cheng, F., Brown, M., Mills, A. A., et al. (2006). p63 regulates an adhesion programme and cell survival in epithelial cells. *Nature Cell Biology, 6*, 551–561.

88. Sato, K., Tomizawa, Y., Iijima, H., Saito, R., Ishizuka, T., Nakajima, T., et al. (2006). Epigenetic inactivation of the RUNX3 gene in lung cancer. *Oncology Reports, 15*(1), 129–135.

89. Zamisch, M., Tian, L., Grenningloh, R., Xiong, Y., Wildt, K. F., Ehlers, M., et al. (2009). The transcription factor Ets1 is important for CD4 repression and Runx3 up-regulation during CD8 T cell differentiation in the thymus. *The Journal of Experimental Medicine, 206*(12), 2685–2699.

90. Lee, K. S., Lee, Y. S., Lee, J. M., Ito, K., Cinghu, S., Kim, J. H., et al. (2010). Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. *Oncogene, 29*(23), 3349–3361.

91. Chang, T. L., Ito, K., Ko, T. K., Liu, Q., Salto-Tellez, M., Yeoh, K. G., et al. (2010). Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. *Gastroenterology, 138*(1), 255–265. e1–3.

92. Lopardo, T., Lo Iacono, N., Marinari, B., Giustizieri, M. L., Cyr, D. G., Merlo, G., et al. (2008). Claudin-1 is a p63 target gene with a crucial role in epithelial development. *PLoS ONE, 3*(7), e2715.

93. Chao, Y. C., Pan, S. H., Yang, S. C., Yu, S. L., Che, T. F., Lin, C. W., et al. (2009). Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. *American Journal of Respiratory and Critical Care Medicine, 179*(2), 123–133.

94. Berger, A. H., Niki, M., Morotti, A., Taylor, B. S., Socci, N. D., Viale, A., et al. (2010). Identification of DOK genes as lung tumor suppressors. *Nature Genetics, 42*(3), 216–223.

95. Niki, M., Di Cristofano, A., Zhao, M., Honda, H., Hirai, H., Van Aelst, L., et al. (2004). Role of Dok-1 and Dok-2 in leukemia suppression. *The Journal of Experimental Medicine, 200*(12), 1689–1695.

96. Wu, G., Nomoto, S., Hoque, M. O., Dracheva, T., Osada, M., Lee, C. C., et al. (2003). DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. *Cancer Research, 63*(10), 2351–2357.

97. Zamò, A., Malpeli, G., Scarpa, A., Doglioni, C., Chilosi, M., & Menestrina, F. (2005). Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas. *Modern Pathology, 18*(11), 1448–1453.

98. Pruneri, G., Fabris, S., Dell'Orto, P., Biasi, M. O., Valentini, S., Del Curto, B., et al. (2005). The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. *The Journal of Pathology, 206*(3), 337–345.

99. Nicolas, M., Koster, M. I., Lu, S. L., White, L. D., Wang, X. J., & Roop, D. R. (2006). Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression. *Cancer Research, 66*(8), 3981–3986.

100. Sasaki, Y., Ishida, S., Morimoto, I., Yamashita, T., Kojima, T., Kihara, C., et al. (2002). The p53 family member genes are involved in the Notch signal pathway. *The Journal of Biological Chemistry, 277*(1), 719–724.

101. Shimomura, Y., Wajid, M., Shapiro, L., & Christiano, A. M. (2008). P-cadherin is a p63 target gene with a crucial role in the developing human limb bud and hair follicle. *Development, 135*(4), 743–753.

102. Taniuchi, K., Nakagawa, H., Hosokawa, M., Nakamura, T., Eguchi, H., Ohigashi, H., et al. (2005). Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. *Cancer Research, 65*(8), 3092–3099.

103. Bui, T., Sequeira, J., Wen, T. C., Sola, A., Higashi, Y., Kondoh, H., et al. (2009). ZEB1 links p63 and p73 in a novel neuronal survival pathway rapidly induced in response to cortical ischemia. *PLoS ONE, 4*(2), e4373. PLoS One. 4(8):e6816.

104. Nicolas, M., Wolfer, A., Raj, K., Kummer, J. A., Mill, P., van Noort, M., et al. (2003). Notch1 functions as a tumor suppressor in mouse skin. *Nature Genetics, 33*(3), 416–421.

105. Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., 4th, Silverman, L. B., Sanchez-Irizarry, C., et al. (2004). Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science, 306*(5694), 269–271.

106. Lefort, K., Mandinova, A., Ostano, P., Kolev, V., Calpini, V., Kolfschoten, I., et al. (2007). Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. *Genes & Development, 21*(5), 562–577.

107. Ji, Q., Hao, X., Zhang, M., Tang, W., Yang, M., Li, L., et al. (2009). MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. *PLoS ONE, 4*(8), e6816.

108. Yugawa, T., Narisawa-Saito, M., Yoshimatsu, Y., Haga, K., Ohno, S., Egawa, N., et al. (2010). DeltaNp63alpha repression of the Notch1 gene supports the proliferative capacity of normal human keratinocytes and cervical cancer cells. *Cancer Research, 70*(10), 4034–4044.

109. Dotto, G. P. (2009). Crosstalk of Notch with p53 and p63 in cancer growth control. *Nature Reviews. Cancer, 8*, 587–595.

110. Schwamborn, J. C., Berezikov, E., & Knoblich, J. A. (2009). The TRIM-NHL protein TRIM32 activates miRNAs and prevents self-renewal in mouse neural progenitors. *Cell, 136*(5), 913–925.

111. Loedige, I., & Filipowicz, W. (2009). TRIM-NHL proteins take on miRNA regulation. *Cell, 136*(5), 818–820.

112. Boominathan, L. (2009). Tumor suppressors function as a bottleneck against cellular reprogramming into iPS cells. *Nature Precedings* http://dx.doi.org/10.1038/npre.2009.4113.1.

113. Boominathan, L. (2010). The tumor suppressors p53, p63 and p73 are regulators of miRNA processing complex. *PLoS ONE, 5*(5), e10615.

114. Viganò, M. A., Lamartine, J., Testoni, B., Merico, D., Alotto, D., Castagnoli, C., et al. (2006). New p63 targets in keratinocytes identified by a genome-wide approach. *The EMBO Journal, 25*(21), 5105–5116.

115. Lee, M., & Vasioukhin, V. (2008). Cell polarity and cancer–cell and tissue polarity as a non-canonical tumor suppressor. *Journal of Cell Science, 121*(Pt 8), 1141–1150.

116. Wodarz, A., & Gonzalez, C. (2006). Connecting cancer to the asymmetric division of stem cells. *Cell, 124*(6), 1121–1123.

117. Boominathan, L. (2010) The TA-p73 functions as a Lung tumor suppressor by increasing the expression of miRNA, let-7. *Nature Precedings* http://dx.doi.org/10.1038/npre.2010.4252.1>.

118. Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., et al. (2007). Differential regulation of miRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. *Cell Cycle, 6*(13), 1586–1593.

119. Rosenbluth, J. M., Mays, D. J., Pino, M. F., Tang, L. J., & Pietenpol, J. A. (2008). A gene signature-based approach identifies mTOR as a regulator of p73. *Molecular and Cellular Biology, 19*, 5951–5964.

120. Kumar, M. S., Erkeland, S. J., Pester, R. E., Chen, C. Y., Ebert, M. S., Sharp, P. A., et al. (2008). Suppression of non-small cell lung tumor development by the let-7 miRNA family. *Proceedings of the National Academy of Sciences of the United States of America, 105*(10), 3903–3908.

121. Esquela-Kerscher, A., Trang, P., Wiggins, J. F., Patrawala, L., Cheng, A., Ford, L., et al. (2008). The let-7 miRNA reduces tumor growth in mouse models of lung cancer. *Cell Cycle, 7*(6), 759–764.

122. Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., et al. (2004). Reduced expression of the let-7 miRNAs in human lung cancers in association with shortened postoperative surviva. *Cancer Research, 64*(11), 3753–3756.

123. Johnson, C. D., Esquela-Kerscher, A., Stefani, G., Byrom, M., & Kelnar, K. (2007). The let-7 miRNA represses cell proliferation pathways in human cells. *Cancer Research, 67*(16), 7713–7722.

124. Baker, D. J., Perez-Terzic, C., Jin, F., Pitel, K., Niederländer, N. J., et al. (2008). Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. *Nature Cell Biology, 10*(7), 825–836.

125. Bearzatto, A., Conte, D., Frattini, M., Zaffaroni, N., Andriani, F., et al. (2002). p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. *Clinical Cancer Research, 8*(12), 3782–3787.

126. Seike, M., Gemma, A., Hosoya, Y., Hemmi, S., Taniguchi, Y., et al. (2000). Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53. *Clinical Cancer Research, 6*(11), 4307–4313.

127. Lee, H. (2003). Impaired phosphorylation and mis-localization of Bub1 and BubR1 are responsible for the defective mitotic checkpoint function in Brca2-mutant thymic lymphomas. *Experimental & Molecular Medicine, 35*(5), 448–453.

128. Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan-Smith, E., Dalton, J. D., et al. (2007). Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature, 446*(7137), 758–764.

129. Yang, A., Zhu, Z., Kapranov, P., McKeon, F., Church, G. M., Gingeras, T. R., et al. (2006). Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. *Molecular Cell, 24*(4), 593–602.

130. Zhang, J., Jun Cho, S., & Chen, X. (2010). RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. *Proceedings of the National Academy of Sciences of the United States of America, 107*(21), 9614–9619.

131. Boominathan, L. (2006) Role of c-Jun in the regulation of the tumor suppressor p53 homologue, p73. Ph.D thesis, *National University of Singapore*, https://scholarbank.nus.edu.sg/handle/10635/15006.

132. Lena, A. M., Shalom-Feuerstein, R., Rivetti di Val Cervo, P., Aberdam, D., Knight, R. A., Melino, G., et al. (2008). miR-203 represses 'stemness' by repressing DeltaNp63. *Cell Death and Differentiation, 15*(7), 1187–1195.

133. Lin, H. K., Chen, Z., Wang, G., Nardella, C., Lee, S. W., Chan, C. H., et al. (2010). Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. *Nature, 464*(7287), 374–379.

134. Chan, C. H., Lee, S. W., Li, C. F., Wang, J., Yang, W. L., Wu, C. Y., et al. (2010). Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. *Nature Cell Biology, 12*(5), 457–467.

135. Zhang, S., Tang, Q., Xu, F., Xue, Y., Zhen, Z., Deng, Y., et al. (2009). RhoA regulates G1-S progression of gastric cancer cells by modulation of multiple INK4 family tumor suppressors. *Molecular Cancer Research, 7*(4), 570–580.

136. Tedesco, D., Lukas, J., & Reed, S. I. (2002). The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). *Genes & Development, 16*(22), 2946–2957.

137. Kitagawa, M., Lee, S. H., & McCormick, F. (2008). Skp2 suppresses p53-dependent apoptosis by inhibiting p300. *Molecular Cell, 29*(2), 217–231.

138. Belletti, B., Nicoloso, M. S., Schiappacassi, M., Berton, S., Lovat, F., Wolf, K., et al. (2008). Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. *Molecular Biology of the Cell, 19*(5), 2003–2013.

139. Keller, U. B., Old, J. B., Dorsey, F. C., Nilsson, J. A., Nilsson, L., MacLean, K. H., et al. (2007). Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. *The EMBO Journal, 26*(10), 2562–2574.

140. Schaffer, B. E., Park, K. S., Yiu, G., Conklin, J. F., Lin, C., Burkhart, D. L., et al. (2010). Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. *Cancer Research, 70*(10), 3877–3883.

141. Gonzalez, S., Klatt, P., Delgado, S., Conde, E., Lopez-Rios, F., Sanchez-Cespedes, M., et al. (2006). Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. *Nature, 440*(7084), 702–706.

142. Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., et al. (2009). A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. *Cell, 137*(1), 87–98.

143. Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T., Toffanin, S., et al. (2009). Lin28 enhances tumorigenesis and is associated with advanced human malignancies. *Nature Genetics, 41*(7), 843–848.

144. Lee, Y. S., & Dutta, A. (2007). The tumor suppressor miRNA let-7 represses the HMGA2 oncogene. *Genes & Development, 21*(9), 1025–1030.

145. Nishino, J., Kim, I., Chada, K., & Morrison, S. J. (2008). Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. *Cell, 135*(2), 227–239.

146. Thuault, S., Tan, E. J., Peinado, H., Cano, A., Heldin, C. H., & Moustakas, A. (2008). HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. *The Journal of Biological Chemistry, 283*(48), 33437–33446.

147. Klanrit, P., Taebunpakul, P., Flinterman, M. B., Odell, E. W., Riaz, M. A., Melino, G., et al. (2009). PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers. *Oncogene, 28*(39), 3499–3512.

148. Peter, M. E. (2009). Let-7 and miR-200 miRNAs: guardians against pluripotency and cancer progression. *Cell Cycle, 8*(6), 843–852.

149. Boyerinas, B., Park, S. M., Shomron, N., Hedegaard, M. M., Vinther, J., Andersen, J. S., et al. (2008). Identification of let-7-regulated oncofetal genes. *Cancer Research, 68*(8), 2587–2591.

150. Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. *Science, 318*(5858), 1917–1920.

151. Mao, H. J., Perez-losada, J., Wu, J., DelRosario, R., Tsunematsu, R., Nakayama, K. I., et al. (2004). Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. *Nature, 432*, 775–779.

152. Sim, K. G., Zang, Z., Yang, C. M., Bonventre, J. V., & Hsu, S. I. (2004). TRIP-Br links E2F to novel functions in the regulation of cyclin E expression during cell cycle progression and in the maintenance of genomic stability. *Cell Cycle, 3*(10), 1296–1304.

153. Welcker, W., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., et al. (2004). The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. *Proceedings of the National Academy of Sciences of the United States of America, 101*(24), 9085–9090.

154. Onoyama, I., Tsunematsu, R., Matsumoto, A., Kimura, T., de Alborán, I. M., Nakayama, K., et al. (2007). Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. *The Journal of Experimental Medicine, 204*(12), 2875–2888.

155. Matsuoka, S., Oike, Y., Onoyama, I., Iwama, A., Arai, F., & Takubo, K. (2008). Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. *Genes & Development, 22*(8), 986–991.

156. Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., et al. (2009). p53 represses c-Myc through induction of the tumor suppressor miR-145. *Proceedings of the National Academy of Sciences of the United States of America, 106*(9), 3207–3212.

157. Liu, X., Sempere, L. F., Galimberti, F., Freemantle, S. J., Black, C., Dragnev, K. H., et al. (2009). Uncovering growth-suppressive MiRNAs in lung cancer. *Clinical Cancer Research, 15*(4), 1177–1183.

158. Yamasaki, L., Jacks, T., Bronson, R., Goillot, E., Harlow, E., & Dyson, N. J. (1996). Tumor induction and tissue atrophy in mice lacking E2F-1. *Cell, 85*(4), 537–548.

159. Chang, T. C., Zeitels, L. R., Hwang, H. W., Chivukula, R. R., Wentzel, E. A., Dews, M., et al. (2009). Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. *Proceedings of the National Academy of Sciences of the United States of America, 106*(9), 3384–3389.

160. He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., et al. (2005). A miRNA polycistron as a potential human oncogene. *Nature, 435*(7043), 828–833.

161. Ernst, A., Campos, B., Meier, J., Devens, F., Liesenberg, F., Wolter, M., et al. (2010). De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. *Oncogene, 29*(23), 3411–3422.

162. Mendell, J. T. (2008). miRiad roles for the miR-17-92 cluster in development and disease. *Cell, 133*(2), 217–222. Review.

163. Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., et al. (2010). A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. *The Journal of Clinical Investigation, 120*(3), 681–693.

164. Matsubara, H., Takeuchi, T., Nishikawa, E., Yanagisawa, K., Hayashita, Y., Ebi, H., et al. (2007). Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17–92. *Oncogene, 26*(41), 6099–6105.

165. Morris, E. J., Ji, J. Y., Yang, F., Di Stefano, L., Herr, A., Moon, N. S., et al. (2008). E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. *Nature, 455*(7212), 552–556.

166. Zhao, C., Blum, J., Chen, A., Kwon, H. Y., Jung, S. H., Cook, J. M., et al. (2007). Loss of beta-catenin impairs the renewal of normal and CML stem cells *in vivo*. *Cancer Cell, 6*, 528–541.

167. Stuart, S. A., Minami, Y., & Wang, J. Y. (2009). The CML stem cell: evolution of the progenitor. *Cell Cycle, 8*(9), 1338–1343.

168. Yan, H. L., Xue, G., Mei, Q., Wang, Y. Z., Ding, F. X., Liu, M. F., et al. (2009). Repression of the miR-17–92 cluster by p53 has an important function in hypoxia-induced apoptosis. *The EMBO Journal, 28*(18), 2719–2732.

169. Bueno, M. J., Gomez de Cedrón, M., Laresgoiti, U., Fernández-Piqueras, J., Zubiaga, A., & Malumbres, M. (2010). Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signalling. *Molecular and Cellular Biology, 12*, 2983–2995.

170. Mu, P., Han, Y. C., Betel, D., Yao, E., Squatrito, M., Ogrodowski, P., et al. (2009). Genetic dissection of the miR-17 92 cluster of microRNAs in Myc-induced B-cell lymphomas. *Genes & Development, 23*(24), 2806–2811.

171. Rempel, R. E., Mori, S., Gasparetto, M., Glozak, M. A., Andrechek, E. R., Adler, S. B., et al. (2009). A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. *PLoS Genetics, 5*(9), e1000640.

172. Chang, T. C., Yu, D., Lee, Y. S., Wentzel, E. A., Arking, D. E., West, K. M., et al. (2008). Widespread miRNA repression by Myc contributes to tumorigenesis. *Nature Genetics, 40*(1), 43–50.

173. Gao, P., Tchernyshyov, I., Chang, T. C., Lee, Y. S., Kita, K., Ochi, T., et al. (2009). c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature, 458*(7239), 762–765.

174. Watanabe, K., Ozaki, T., Nakagawa, T., Miyazaki, K., Takahashi, M., et al. (2002). Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. *The Journal of Biological Chemistry, 277*(17), 15113–15123.

175. Horvilleur, E., Bauer, M., Goldschneider, D., Mergui, X., de la Motte, A., et al. (2008). p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. *Nucleic Acids Research, 36*(13), 4222–4232.

176. Giuriato, S., Ryeom, S., Fan, A. C., Bachireddy, P., Lynch, R. C., Rioth, M. J., et al. (2006). Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. *Proceedings of the National Academy of Sciences of the United States of America, 103*(44), 16266–16271.

177. Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., et al. (2007). MiRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. *Proceedings of the National Academy of Sciences of the United States of America, 104*(40), 15805–15810.

178. Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C. E., Callegari, E., et al. (2009). MiRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. *Blood, 113*(25), 6411–6418.

179. Deneault, E., Cellot, S., Laverdure, F. A., JP, F. M., Chagraoui, J., et al. (2009). Functional screen to identify novel effectors of hematopoietic stem cell activity. *Cell, 137*(2), 369–379.

180. Wang, H., Garzon, R., Sun, H., Ladner, K. J., Singh, R., Dahlman, J., et al. (2008). NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. *Cancer Cell, 14*(5), 369–381.

181. Park, Y., Lee, J. H., Ha, M., Nam, J. W., & Kim, V. N. (2009). miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. *Nature Structural & Molecular Biology, 16*(1), 23–29.

182. Sinha, A. U., Kaimal, V., Chen, J., & Jegga, A. G. (2008). Dissecting microregulation of a master regulatory network. *BMC Genomics, 9*, 88.

183. Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., et al. (2008). A miRNA DNA methylation signature for human cancer metastasis. *Proceedings of the National Academy of Sciences of the United States of America, 105*(36), 13556–13561.

184. Duursma, A. M., Kedde, M., Schrier, M., le Sage, C., & Agami, R. (2008). miR-148 targets human DNMT3b protein coding region. *RNA, 14*(5), 872–877.

185. Kato, M., Zhang, J., Wang, M., Lanting, L., Yuan, H., Rossi, J. J., et al. (2007). MiRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. *Proceedings of the National Academy of Sciences of the United States of America, 104*(9), 3432–3437.

186. Braun, C. J., Zhang, X., Savelyeva, I., Wolff, S., Moll, U. M., Schepeler, T., et al. (2008). p53-Responsive miRNAs 192 and 215 are capable of inducing cell cycle arrest. *Cancer Research, 68*(24), 1094–1104.

187. Georges, S. A., Biery, M. C., Kim, S. Y., Schelter, J. M., Guo, J., Chang, A. N., et al. (2008). Coordinated regulation of cell cycle transcripts by p53-Inducible miRNAs, miR-192 and miR-215. *Cancer Research, 68*(24), 10105–10112.

188. Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nature Cell Biology, 10*(5), 593–601.

189. Bracken, C. P., Gregory, P. A., Kolesnikoff, N., Bert, A. G., Wang, J., Shannon, M. F., et al. (2008). A double-negative feedback loop between ZEB1-SIP1 and the miRNA-200 family regulates epithelial-mesenchymal transition. *Cancer Research, 68*(19), 7846–7854.

190. Gebeshuber, C. A., Zatloukal, K., & Martinez, J. (2009). miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. *EMBO Reports, 10*(4), 400–405.

191. Sengupta, S., den Boon, J. A., Chen, I. H., Newton, M. A., Stanhope, S. A., Cheng, Y. J., et al. (2008). MiRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. *Proceedings of the National Academy of Sciences of the United States of America, 105*(15), 5874–5878.

192. Qin, L., Liao, L., Redmond, A., Young, L., Yuan, Y., Chen, H., et al. (2008). The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. *Molecular and Cellular Biology, 19*, 5937–5950.

193. Zenz, T., Mohr, J., Eldering, E., Kater, A. P., Buhler, A., Kienle, D., et al. (2009). MiR-34a as part of the resistance network in chronic lymphocytic leukemia. *Blood, 113*(16), 3801–3808.

194. He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., et al. (2007). miRNA component of the p53 tumour suppressor network. *Nature, 447*(7148), 1130–1134.

195. He, L., He, X., Lowe, S. W., & Hannon, G. J. (2007). miRNAs join the p53 network—another piece in the tumour-suppression puzzle. *Nature Reviews. Cancer, 7*(11), 819–822. Review.

196. Sun, F., Fu, H., Liu, Q., Tie, Y., Zhu, J., Xing, R., et al. (2008). Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. *FEBS Letters, 582*(10), 1564–1568.

197. Aslanian, A., Iaquinta, P. J., Verona, R., & Lees, J. A. (2004). Repression of the Arf tumor suppressor by E2F3 is required for

normal cell cycle kinetics. *Genes & Development, 18*(12), 1413–1422.

198. Ji, Q., Hao, X., Meng, Y., Zhang, M., Desano, J., Fan, D., et al. (2008). Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. *BMC Cancer, 8,* 266.

199. Wang, S., Yuan, Y., Liao, L., Kuang, S. Q., Tien, J. C., O'Malley, B. W., et al. (2009). Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. *Proceedings of the National Academy of Sciences of the United States of America, 106*(1), 151–156.

200. Qin, L., Liu, Z., Chen, H., & Xu, J. (2009). The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. *Cancer Research, 69*(9), 3819–3827.

201. Nguyen, D. X., Chiang, A. C., Zhang, X. H., Kim, J. Y., Kris, M. G., Ladanyi, M., et al. (2009). WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. *Cell, 138*(1), 51–62.

202. Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. *Natural Medicines, 14*(11), 1271–1277.

203. Klein, U., Lia, M., Crespo, M., Siegel, R., Shen, Q., Mo, T., et al. (2010). The DLEU2/miR-15a/16–1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. *Cancer Cell, 17*(1), 28–40.

204. Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proceedings of the National Academy of Sciences of the United States of America, 102*(39), 13944–13949.

205. Calin, G. A., Cimmino, A., Fabbri, M., Ferracin, M., Wojcik, S. E., Shimizu, M., et al. (2008). MiR-15a and miR-16-1 cluster functions in human leukemia. *Proceedings of the National Academy of Sciences of the United States of America, 105*(13), 5166–5171.

206. Chatterjee, A., Chang, X., Sen, T., Ravi, R., Bedi, A., & Sidransky, D. (2010). Regulation of p53 family member isoform DeltaNp63alpha by the nuclear factor-kappaB targeting kinase IkappaB kinase beta. *Cancer Research, 70*(4), 1419–1429.

207. Boominathan, L. (2009) Curcumin functions a positive regulator of miRNA processing and a negative regulator of stem cell proliferation. *Nature Precedings*, http://dx.doi.org/10.1038/npre.2009.4110.1

208. Dovey, J. S., Zacharek, S. J., Kim, C. F., & Lees, J. A. (2008). Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. *Proceedings of the National Academy of Sciences of the United States of America, 105* (33), 11857–11862.

209. Bueno, M. J., Gómez de Cedrón, M., Laresgoiti, U., Fernández-Piqueras, J., Zubiaga, A. M., & Malumbres, M. (2010). Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling. *Molecular and Cellular Biology, 30*(12), 2983–2995.

210. Sander, S., Bullinger, L., Klapproth, K., Fiedler, K., Kestler, H. A., Barth, T. F., et al. (2008). MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. *Blood, 112*(10), 4202–4212.

211. Sander, S., Bullinger, L., & Wirth, T. (2009). Repressing the repressor: a new mode of MYC action in lymphomagenesis. *Cell Cycle, 8*(4), 556–559.

212. Fujii, S., & Ochiai, A. (2008). Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. *Cancer Science, 99*(4), 738–746.

213. Fujii, S., Ito, K., Ito, Y., & Ochiai, A. (2008). Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. *The Journal of Biological Chemistry, 283*(25), 17324–17332.

214. Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H., Mani, R. S., Tomlins, S. A., et al. (2008). Repression of E-cadherin by the polycomb group protein EZH2 in cancer. *Oncogene, 27*(58), 7274–7284.

215. Beke, L., Nuytten, M., Van Eynde, A., Beullens, M., & Bollen, M. (2007). The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. *Oncogene, 26*(31), 4590–4595.

216. Yang, X., Karuturi, R. K., Sun, F., Aau, M., Yu, K., Shao, R., et al. (2009). CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. *PLoS ONE, 4*(4), e5011.

217. Ezhkova, E., Pasolli, H. A., Parker, J. S., Stokes, N., Su, I. H., Hannon, G., et al. (2009). Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. *Cell, 136*(6), 1122–1135.

218. Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. *Cell, 137*(6), 1005–1017.

219. Friedman, J. M., Liang, G., Liu, C. C., Wolff, E. M., Tsai, Y. C., et al. (2009). The putative tumor suppressor miRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. *Cancer Research, 69*(6), 2623–2629.

220. Faber, J., Krivtsov, A. V., Stubbs, M. C., Wright, R., Davis, T. N., van den Heuvel-Eibrink, M., et al. (2009). HOXA9 is required for survival in human MLL-rearranged acute leukemias. *Blood, 113*(11), 2375–2385.

221. Rowland, B. D., Bernards, R., & Peeper, D. S. (2005). The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. *Nature Cell Biology, 7* (11), 1074–1082.

222. Li, Y., Zhou, Z., & Chen, C. (2008). WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. *Cell Death and Differentiation, 15*(12), 1941–1951.

223. Yu, F., Deng, H., Yao, H., Liu, Q., Su, F., Song, E. (2010) Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. *Oncogene* (in press)

224. Braun, J., Hoang-Vu, C., Dralle, H., Hüttelmaier, S. (2010) Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. *Oncogene* (in press)

225. Chang, T. C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., et al. (2007). Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. *Molecular Cell, 26*(5), 745–752.

226. Kim, W. Y., Perera, S., Zhou, B., Carretero, J., Yeh, J. J., Heathcote, S. A., et al. (2009). HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. *The Journal of Clinical Investigation, 119*(8), 2160–2170.

227. Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., et al. (2009). Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. *Cancer Cell, 15*(6), 501–513.

228. Keith, B., & Simon, M. C. (2007). Hypoxia-inducible factors, stem cells, and cancer. *Cell, 129*(3), 465–472. Review.

229. Gordan, J. D., & Simon, M. C. (2007). Hypoxia-inducible factors: central regulators of the tumor phenotype. *Current Opinion in Genetics & Development, 17*(1), 71–77. Review.

230. Gort, E. H., Groot, A. J., van der Wall, E., van Diest, P. J., & Vooijs, M. A. (2008). Hypoxic regulation of metastasis via hypoxia-inducible factors. *Current Molecular Medicine, 8*(1), 60–67. Review.

231. Jazdzewski, K., Murray, E. L., Franssila, K., Jarzab, B., Schoenberg, D. R., & de la Chapelle, A. (2008). Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. *Proceedings of the*

National Academy of Sciences of the United States of America, 105(20), 7269–7274.

232. Jazdzewski, K., Liyanarachchi, S., Swierniak, M., Pachucki, J., Ringel, M. D., Jarzab, B., et al. (2009). Polymorphic mature miRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. *Proceedings of the National Academy of Sciences of the United States of America, 106*(5), 1502–1505.

233. Lin, S. L., Chiang, A., Chang, D., & Ying, S. Y. (2008). Loss of mir-146a function in hormone-refractory prostate cancer. *RNA, 14*(3), 417–424.

234. Hurst, D. R., Edmonds, M. D., Scott, G. K., Benz, C. C., Vaidya, K. S., & Welch, D. R. (2009). Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. *Cancer Research, 69*(4), 1279–1283.

235. Onder, T. T., Gupta, P. B., Mani, S. A., Yang, J., Lander, E. S., & Weinberg, R. A. (2008). Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. *Cancer Research, 68*(10), 3645–3654.

236. Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The epithelial–mesenchymal transition generates cells with properties of stem cells. *Cell, 133*(4), 704–715.

237. Khew-Goodall, Y., & Goodall, G. J. (2010). Myc-modulated miR-9 makes more metastases. *Nature Cell Biology, 12*(3), 209–211.

238. Ma, L., Young, J., Prabhala, H., Pan, E., Mestdagh, P., Muth, D., et al. (2010). miR-9, a MYC/MYCN-activated miRNA, regulates E-cadherin and cancer metastasis. *Nature Cell Biology, 12*(3), 247–256.

239. Smith, S. C., & Theodorescu, D. (2009). Learning therapeutic lessons from metastasis suppressor proteins. *Nature Reviews. Cancer, 9*(4), 253–264.

240. Kim, J. W., Mori, S., & Nevins, J. R. (2010). Myc-induced MicroRNAs integrate Myc-mediated cell proliferation and cell fate. *Cancer Research, 70*(12), 4820–4828.

241. Garofalo, M., Di Leva, G., Romano, G., Nuovo, G., Suh, S. S., Ngankeu, A., et al. (2009). miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. *Cancer Cell, 16*(6), 498–509.

242. Fornari, F., Gramantieri, L., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G. A., et al. (2008). MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepato-cellular carcinoma. *Oncogene, 27*(43), 5651–5661.

243. Wu, C. H., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., & Felsher, D. W. (2007). Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. *Proceedings of the National Academy of Sciences of the United States of America, 104*(32), 13028–13033.

244. Guney, I., Wu, S., & Sedivy, J. M. (2006). Reduced c-Myc signaling triggers telomere independent senescence by regulating Bmi-1 and p16(INK4a). *Proceedings of the National Academy of Sciences of the United States of America, 103*(10), 3645–3650.

245. Nemajerova, A., Petrenko, O., Trümper, L., Palacios, G., & Moll, U. M. (2010). Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. *The Journal of Clinical Investigation, 120*(6), 2070–2080.

246. Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A. J., et al. (2008). p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. *Nature, 455*(7216), 1129–1133.

247. Liu, X., Karnell, JL., Yin, B., Zhang, R., Zhang, J., Li, P., et al. (2010) Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. *J Clin Invest* (in press)

248. Guo, W., Lasky, J. L., Chang, C. J., Mosessian, S., Lewis, X., Xiao, Y., et al. (2008). Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. *Nature, 453*(7194), 529–533.

249. Yanagi, S., Kishimoto, H., Kawahara, K., Sasaki, T., Sasaki, M., Nishio, M., et al. (2007). Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. *The Journal of Clinical Investigation, 117*(10), 2929–2940.

250. Du, L., & Pertsemlidis, A. (2010). microRNAs and lung cancer: tumors and 22-mers. *Cancer and Metastasis Reviews, 29*(1), 109–122. Review.

251. Gregory, M. A., Qi, Y., & Hann, S. R. (2005). The ARF tumor suppressor: keeping Myc on a leash. *Cell Cycle, 4*(2), 24952.

252. Nicholson, S. A., Okby, N. T., Khan, M. A., Welsh, J. A., McMenamin, M. G., Travis, W. D., et al. (2001). Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. *Cancer Research, 61*(14), 5636–5643.

253. Inoue, K., Mallakin, A., & Frazier, D. P. (2007). Dmp1 and tumor suppression. *Oncogene, 26*(30), 4329–4335. Review.

254. Mallakin, A., Sugiyama, T., Taneja, P., Matise, L. A., Frazier, D. P., Choudhary, M., et al. (2007). Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. *Cancer Cell, 12*(4), 381–394.

255. Inoue, K., Sugiyama, T., Taneja, P., Morgan, R. L., & Frazier, D. P. (2008). Emerging roles of DMP1 in lung cancer. *Cancer Research, 68*(12), 4487–4490. Review.

256. Malone, & Hannon. (2009). Small RNAs as guardians of the genome. *Cell, 136*, 656–668.

257. Xi, Y., Shalgi, R., Fodstad, O., Pilpel, Y., & Ju, J. (2006). Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. *Clinical Cancer Research, 12*(7 Pt 1), 2014–2024.

258. Theurkauf, W. E., Klattenhoff, C., Bratu, D. P., McGinnis-Schultz, N., Koppetsch, B. S., & Cook, H. A. (2006). rasiRNAs, DNA damage, and embryonic axis specification. *Cold Spring Harbor Symposia on Quantitative Biology, 71*, 171–180.

259. Kutter, C., & Svoboda, P. (2008). miRNA, siRNA, piRNA: knowns of the unknown. *RNA Biology, 5*(4), 181–188.

260. Boominathan, L. (2009). The guardians of the genome dependent tumor suppressor miRNAs network *Nature Precedings*, http://dx.doi.org/10.1038/npre.2009.4112.1